



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/25, G01N 33/68, 33/58		A1	(11) International Publication Number: WO 96/33286
(21) International Application Number: PCT/US96/05643		(43) International Publication Date: 24 October 1996 (24.10.96)	
(22) International Filing Date: 19 April 1996 (19.04.96)		(81) Designated States: AU, CA, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/425,299 20 April 1995 (20.04.95) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 77 Quincy Street, Cambridge, MA 02138 (US).			
(72) Inventors: KIRSCHNER, Marc, W.; 20 Garlyann Road, Newton, MA 02159 (US). KING, Randall, W.; 310 Tappin Street #5, Brookline, MA 02146 (US). PETERS, Jan-Michael; 32 Parkway Road, Brookline, MA 02146 (US).			
(74) Agents: VINCENT, Matthew, P. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).			

(54) Title: ASSAY AND REAGENTS FOR DETECTING INHIBITORS OF UBIQUITIN-DEPENDENT DEGRADATION OF CELL CYCLE REGULATORY PROTEINS

(57) Abstract

The present invention provides a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as cyclins. One aspect of the present invention relates to a method for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein by (i) providing a ubiquitin-conjugating system that includes the regulatory protein and ubiquitin under conditions which promote the ubiquitination of the target protein, and (ii) measuring the level of ubiquitination of the subject protein brought about by the system in the presence and absence of a candidate agent. A decrease in the level of ubiquitin conjugation is indicative of an inhibitory activity for the candidate agent. The level of ubiquitination of the regulatory protein can be measured by determining the actual concentration of protein:ubiquitin conjugates formed; or inferred by detecting some other quality of the subject protein affected by ubiquitination, including the proteolytic degradation of the protein.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Assay and Reagents for Detecting Inhibitors of Ubiquitin-
dependent Degradation of Cell Cycle Regulatory Proteins

Background of the Invention

5 The ubiquitin-mediated proteolysis system is the major pathway for the selective, controlled degradation of intracellular proteins in eukaryotic cells. Ubiquitin modification of a variety of protein targets within the cell appears to be important in a number of basic cellular functions such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. For
10 instance, several key regulatory proteins are known to be degraded through the ubiquitin-mediated pathway, including certain transcriptional regulators, key enzymes of metabolic pathways, cyclins, and the tumor suppressor p53. One major function of the ubiquitin-mediated system is to control the half-lives of cellular proteins. The half-life of different proteins can range from a few minutes to several days, and can vary considerably depending
15 on the cell-type, nutritional and environmental conditions, as well as the stage of the cell-cycle.

Targeted proteins undergoing selective degradation are covalently tagged with ubiquitin (Ub) through the formation of an isopeptide bond between the C-terminal glycyl residue of ubiquitin and a specific lysyl residue in the substrate protein. This process is catalyzed by a
20 ubiquitin-activating enzyme (E1) and a ubiquitin-conjugating enzyme (E2), and in some instances may also require auxiliary substrate recognition proteins (E3s). Following the linkage of the first ubiquitin chain, additional molecules of ubiquitin may be attached to lysine side chains of the previously conjugated moiety to form branched multi-ubiquitin chains.

25 The conjugation of ubiquitin to protein substrates is a multi-step process (for a review, see, e.g., Chiechanover, (1994) *Cell* 79:13-21). In an initial ATP requiring step, a thioester is formed between the C-terminus of ubiquitin and an internal cysteine residue of an E1 enzyme. Activated ubiquitin is then transferred to a specific cysteine on one of several E2 enzymes. Finally, these E2 enzymes donate ubiquitin to protein substrates. Substrates are
30 recognized either directly by ubiquitin-conjugated enzymes or by associated substrate recognition proteins, the E3 proteins.

Ubiquitin is itself a substrate for ubiquitination. Depending on the ubiquitin-conjugating enzyme and the nature of the substrate, specific lysine residues of ubiquitin are used as acceptor sites for further ubiquitinations. This can lead to either a linear multi-ubiquitin
35 chain (when a single lysine residue of ubiquitin is used) or multi-ubiquitin "trees" (when

more than one lysine residue of ubiquitin is used). Although the attachment of a single ubiquitin moiety to a substrate can be sufficient for degradation, multi-ubiquitination appears to be required in most cases.

Many proteins that control cell-cycle progression are short-lived. For example, regulation of oncoproteins and anti-oncoproteins clearly plays an important role in determining steady-state levels of protein expression, and alterations in protein degradation are as likely as changes in transcription and/or translation to cause either the proliferative arrest of cells, or alternatively, the transformation of cells. Therefore, it is an object of this invention to provide an assay for identifying inhibitors of ubiquitin-mediated degradation of such regulatory proteins. As described below, such inhibitors can ultimately be of therapeutic significance as anti-proliferative agents in the treatment of cancer, pathogenic infection, and even as immunosuppressants.

Summary of the Invention

The present invention provides a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein in cells from vertebrate organism, especially mammals, preferably humans. For instance, the assays permit identification of agents which inhibit ubiquitination of the cyclin proteins, e.g., B-type cyclins. One aspect of the present invention relates to a method for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein by (i) providing a ubiquitin-conjugating system that includes the regulatory protein, a mitotic destruction complex (e.g., comprising CDC27 and CDC16), and ubiquitin under conditions which promote the ubiquitination of the target protein, and (ii) measuring the level of ubiquitination of the subject protein brought about by the system in the presence and absence of a candidate agent. A decrease in the level of ubiquitin conjugation is indicative of an inhibitory activity for the candidate agent. The level of ubiquitination of the regulatory protein can be measured by determining the actual concentration of protein:ubiquitin conjugates formed; or inferred by detecting some other quality of the subject protein affected by ubiquitination, including the proteolytic degradation of the protein. In certain embodiments, the present assay comprises an *in vivo* ubiquitin-conjugating system, such as a cell able to conduct the regulatory protein through at least a portion of a ubiquitin-mediated proteolytic pathway. In other embodiments, the present assay comprises an *in vitro* ubiquitin-conjugating system comprising a reconstituted protein mixture in which at least the ability to transfer ubiquitin to the regulatory protein is constituted.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology,

- microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985);
- 5 *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No. 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology*
- 10 (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); and *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986).
- 15 Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings

Figure 1 is a scheme which shows the fractionation of Mitotic Xenopus egg extracts.

- 20 Figure 2 shows the dose-response curve of the ability of UBC2 and UBC4 to complement fraction Q2.

Detailed Description of the Invention

- The ubiquitin system is essential for a wide spectrum of cellular phenomena, and is a
- 25 component of many biological regulatory mechanisms, including aspects of growth control, metabolic regulation, embryonic development, and cell-cycle progression. The present invention makes available drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as the regulatory cyclin proteins, in the
- 30 cells of vertebrate organisms, e.g. mammals, e.g., humans.

In particular, the present invention is derived from the discovery that a "mitotic destruction complex" or "MDC", comprising the CDC27 and CDC16 proteins, is required in the cells of vertebrate organisms for ubiquitination of certain regulated proteins, which MDC functions with the apparent role of an E3. Accordingly, the subject assay, which can be used

to identify agents that modulate MDC-dependent ubiquitination, comprises a ubiquitin-conjugating system that includes the regulatory protein, a CDC27/CDC16 complex, and ubiquitin, and provides conditions which promote the ubiquitination of the target protein. The level of ubiquitination of the target protein brought about by the system is measured in the presence and absence of a candidate agent, wherein a statistically significant decrease in the level of ubiquitin conjugation indicates an inhibitory activity for the candidate agent. Likewise, an increase in the level of ubiquitination is indicative of a potentiating activity of the test agent. As described below, the level of ubiquitination of the regulatory protein can be measured by determining the actual concentration of target protein:ubiquitin conjugates formed; or inferred by detecting some other quality of the subject protein affected by ubiquitination, including the proteolytic degradation of the protein. In preferred embodiments, the present assay comprises an *in vitro* ubiquitin-conjugating system in which at least the ability to transfer ubiquitin to the regulatory protein is constituted.

As described herein, inhibitors of the ubiquitin-mediated proteolysis of the regulatory protein refer generally to those agents which may act anywhere along the ubiquitin degradation pathway; from the reaction steps leading up to an including conjugation of ubiquitin to the protein of interest, to the interaction and degradation of the ubiquitin conjugate by a proteasome complex. A subset of this class of inhibitors comprises the ubiquitination inhibitors, which include those agents that act at the level of preventing conjugation of ubiquitin to the subject protein, rather than at the steps of proteolytic degradation of the protein. As more fully illustrated below, this subset of inhibitors is directed more particularly to such steps as the activation of ubiquitin by E1, transfer of ubiquitin from E1 to E2, or transfer of the activated ubiquitin to the target regulatory protein from the E2:Ub conjugate via a CDC27/CDC16 complex. Likewise, protease inhibitors refer to that subset of inhibitors which act at the step of proteasome-catalyzed degradation of the regulatory protein:ubiquitin conjugate. Moreover, as will be clear from the following description, particular embodiments of the present assay can be chosen so as to discriminate between ubiquitination inhibitors and protease inhibitors.

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The term "mitotic destruction complex" or "MDC" refers to a protein complex including a CDC27 protein and a CDC16 protein, which protein complex augments or otherwise facilitates the ubiquitination of a protein. In preferred embodiments, the MDC is a multi-protein complex which sediments by sucrose gradient centrifugation as an approximately 20S complex, e.g., in the range of 18S to 22S.

As used herein "MDC-dependent ubiquitination" refers to the conjugation of ubiquitin to a protein by a mechanism which requires the mitotic destruction complex for efficiency.

The term "target protein" refers to a protein, preferably a cellular protein, which can be ubiquitinated by an MDC-dependent reaction pathway.

5 The term "whole lysate" refers to a cell lysate which has not been manipulated, e.g. either fractionated, depleted or charged, beyond the step of merely lysing the cell to form the lysate. The term whole cell lysate does not, however, include lysates derived from cells which produce recombinant forms of one or more of the proteins required to constitute a ubiquitin-conjugating system for MDC-dependent ubiquitination of a target protein.

10 The term "charged lysate" refers to cell lysates which have been spiked with exogenous, e.g., purified, semi-purified and/or recombinant, forms of one or more components of an MDC-dependent ubiquitin-conjugating system, or the target protein thereof. The lysate can be charged after the whole cells have been harvested and lysed, or alternatively, by virtue of the cell from which the lysate is formed expressing a recombinant form of one or more of the conjugating system components.

15 The term "semi-purified cell extract" or, alternatively, "fractionated lysate", as used herein, refers to a cell lysate which has been treated so as to substantially remove at least one component of the whole cell lysate, or to substantially enrich at least one component of the whole cell lysate. "Substantially remove", as used herein, means to remove at least 10%, more preferably at least 50%, and still more preferably at least 80%, of the component of the whole cell lysate. "Substantially enrich", as used herein, means to enrich by at least 10%,
20 more preferably by at least 30%, and still more preferably at least about 50%, at least one component of the whole cell lysate compared to another component of the whole cell lysate. The component which is removed or enriched can be a component of a ubiquitin-conjugation pathway, e.g., ubiquitin, a target protein, an E1, an E2, a CDC27, a CDC16, a cyclin, and the like, or it can be a component which can interfere with a ubiquitin-binding assay, e.g., a
25 protease.

The term "semi-purified cell extract" is also intended to include the lysate from a cell, when the cell has been treated so as to have substantially more, or substantially less, of a given component than a control cell. For example, a cell which has been modified (by, e.g., recombinant DNA techniques) to produce none (or very little) of a component of a ubiquitin-conjugation pathway, will, upon cell lysis, yield a semi-purified cell extract.
30

The term "component of a ubiquitin-conjugation pathway", as used herein, refers to a component which can participate in the ubiquitination of a target protein either *in vivo* or *in vitro*. Exemplary components of a ubiquitin-conjugation pathway include ubiquitin, an E1, an E2, an E3, a CDC27/CDC16 complex, a target protein, and the like.

35 By "semi-purified", with respect to protein preparations, it is meant that the proteins have been previously separated from other cellular or viral proteins. For instance, in contrast

to whole cell lysates, the proteins of reconstituted conjugation system, together with the target protein, can be present in the mixture to at least 50% purity relative to all other proteins in the mixture, more preferably are present at at least 75% purity, and even more preferably are present at 90-95% purity.

5 The term "purified protein" refers to a preparation of a protein or proteins which are preferably isolated from, or otherwise substantially free of, other proteins normally associated with the protein(s) in a cell or cell lysate. The term "substantially free of other cellular proteins" (also referred to herein as "contaminating proteins") is defined as encompassing individual preparations of each of the component proteins comprising less than 20% (by dry weight) contaminating protein, and preferably comprises less than 5% contaminating protein. 10 Functional forms of each of the component proteins can be prepared as purified preparations by using a cloned gene as described in the attached examples. By "purified", it is meant, when referring to the component proteins preparations used to generate the reconstituted protein mixture, that the indicated molecule is present in the substantial absence of other 15 biological macromolecules, such as other proteins (particularly other proteins which may substantially mask, diminish, confuse or alter the characteristics of the component proteins either as purified preparations or in their function in the subject reconstituted mixture). The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of 20 biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above. "Isolated" and "purified" do not encompass either protein in its native state (e.g. as a part of a cell), or as part of a cell lysate, or that have been separated into 25 components (e.g., in an acrylamide gel) but not obtained either as pure (e.g. lacking contaminating proteins) substances or solutions. The term isolated as used herein also refers to a component protein that is substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

30 The term "gene" or "recombinant gene" refers to a nucleic acid comprising an open reading frame encoding a protein of the present invention, including both exon and (optionally) intron sequences. Exemplary recombinant genes encoding components of the subject ubiquitin conjugating systems include nucleic acids encoding CDC27, CDC16, ubiquitin conjugating enzymes, such as UBC4 or UBC5, and ubiquitin.

35 The term "recombinant protein" refers to a protein of the present ubiquitin conjugating systems which is produced by recombinant DNA techniques, wherein generally DNA encoding, for example, an E2 enzyme, a component of the MDC, or a target protein, is

inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein.

As used herein, the term "transfection" refers to the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer.

5 "Transformation", as used herein, refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of a protein of the present ubiquitin conjugating systems.

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is
10 an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility
15 in recombinant DNA techniques are often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

20 "Homology" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the
25 number of matching or homologous positions shared by the sequences.

"Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may
30 not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A "chimeric protein" or "fusion protein" is a fusion of a first amino acid sequence encoding one of the proteins of the subject ubiquitination assays with a second amino acid sequence defining a domain foreign to and not substantially homologous with any domain of
35 the first protein. A chimeric protein may present a foreign domain which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an

"interspecies", "intergeneric", etc. fusion of protein structures expressed by different kinds of organisms. An exemplary fusion protein is a cyclin B/glutathione-s-transferase fusion protein.

I. Target Proteins

5 In a preferred embodiment, the target protein is a cyclin, particularly a cyclin having a cyclin destruction box, e.g., a B-type cyclin. In general, cyclin degradation is a key step governing exit from mitosis and progression into the next cell-cycle. For example, the transition from metaphase to anaphase, which marks the end of mitosis, is induced by the degradation of cyclin B by a ubiquitin-mediated pathway, which in turn leads to the
10 inactivation of cyclin-dependent kinases (cdk) operational at that cell-cycle stage. As cells enter interphase, cyclin degradation ceases, cyclin accumulates and, as a result of a complex series of post-translational modifications, cyclin B/cdk complexes are activated as kinases which drive the cell through mitosis. Cyclin B degradation is thus one of the crucial events in exiting mitosis (see, e.g., King *et al.* (1994) *Cell* 79:563). Indeed, cyclin mutants that
15 retain the ability to activate the cdk complexes, but which cannot be degraded, arrest the cell-cycle in mitosis. Similar cyclin-dependence exists at other points of the cell-cycle as well. Thus, inhibitors of ubiquitin-mediated degradation of a cyclin (such as where the cyclin is chosen from cyclin A, B, C, D1, D2, D3, E, F, G or H) can be used as antiproliferative agents.

20 The N-termini of mitotic cyclins contain a short conserved sequence, called the destruction box, that is required for their degradation (Glutzer *et al.* (1991) *Nature* 349:132). The cyclin ubiquitination reaction is unusual in that it is specified at two levels: substrate recognition which is reflected in the requirement for an intact destruction box, and temporal control in the limitation of its activity to a specific phase of the cell cycle, late mitosis and
25 early G1 (see, e.g., Amon *et al.*, (1994) *Cell* 77:1037).

In other embodiments of the subject assay, the target regulatory protein is the tumor suppressor p53, and the assay is used to identify inhibitors of ubiquitin-mediated destruction of p53. Many lines of evidence point to the importance of p53 in human carcinogenesis. For instance, mutations within the p53 gene are the most frequent genetic aberration thus far
30 associated with human cancer. Under normal conditions, p53 is an unstable protein and is present at very low levels in the cell, and the level of p53 in a cell appears to be controlled at least in part by degradation involving the ubiquitin system. Treating cells with UV light or X rays dramatically reduces the rate of p53 degradation, leading to a rapid increase in its concentration in the cell and presumably inducing the transcription of genes that block
35 passage through the restriction point. However, while normal cell lines irradiated in G1 fail to enter S phase, many tumor lines do not. In fact, there is a perfect correlation between cell lines that lack this feedback control and cells that have mutations in the p53 gene. These

mutations are of two sorts: recessive mutations that inactivate the gene, and dominant mutations that produce abnormal proteins. An inhibitor developed using the subject assay could be used therapeutically to enhance the function of the p53 checkpoint by increasing the steady state concentration of p53 in the treated cell. The anti-proliferative activity of such an inhibitor can be employed in the treatment of hyperplasias or neoplasias by increasing the fortitude of the checkpoint in transformed cells which contain wild-type p53 (i.e. can induce apoptosis in cells overexpressing *c-myc*), or by offsetting a diminishment in p53 activity by increasing the level of (mutant) p53. Moreover, such agents can also be used prophylactically to increase p53 levels and thereby enhance the protection against DNA damaging agents when it is known that exposure to damaging agents, such as radiation, is imminent.

In yet another embodiment, the targeted regulatory protein is the *myc* oncoprotein. The *myc* regulatory protein is activated by translocation or mutation in many B-cell lymphomas or by amplification in tumor types, such as small cell lung cancer and breast cancer. The *c-myc* gene is the cellular homolog of the viral oncogene *v-myc*, which is found in a number of avian and feline retroviruses which induce leukemia and carcinomas. The *myc* protein has been implicated in the control of normal cell proliferation by many studies. In particular, it is one of the immediate early growth response genes that are rapidly induced in quiescent cells upon mitogenic induction, suggesting that it plays some role in mediating the transition from quiescence to proliferation. However, increased levels of *myc* itself is not sufficient to cause proliferation. In fact, in normal cells the opposite happens and the cell undergoes apoptosis. Therefore, inhibitors identified in the present assay can be used to effectively induce apoptosis in cells which do not normally overexpress *myc*. For example, specific delivery of these agents to lymphocytes can be used to inhibit proliferation of B- and/or T-cells in order to induce clonal deletion and generate tolerance to particular antigens.

In tumor cells, on the other hand, elevated or deregulated expression of *c-myc* is so widespread as to suggest a critical role for *myc* gene activation in multi-stage carcinomas (Field et al. (1990) *Anticancer Res* 10:1-22; and Spencer et al. (1991) *Adv Cancer Res* 56:1-48). However, such overexpression of *myc* in these cells is typically believed to be accompanied by expression of other cellular proteins, such as *bcl-2*. Interestingly, however, almost all tumor cells tested that overexpress *myc* readily undergo apoptosis in the presence of cytotoxic and growth-inhibitory drugs (Cotter et al. (1990) *Anticancer Res* 10:1153-1159; and Lennon et al. (1990) *Biochem Soc Trans* 18:343-345). Therefore, inhibitors of the ubiquitin-mediated degradation of *myc* can be used to further deregulate the expression of *myc* in order to render the cells even more sensitive to a chemotherapeutic treatment, or to possibly upset the careful balance of the transformed cell and cause apoptosis to occur even in the absence of a second cytotoxic drug.

Still another target protein which may undergo MDC-mediated ubiquitination is the AP-1 component, *c-fos*. The *fos* oncogene product, which can undergo ubiquitin-mediated degradation in a cell, has been implicated in neoplastic transformation as well as in mediating the action of a variety of extracellular stimuli. The control of gene expression by *c-fos* is believed to play a critical role in cellular proliferation and developmental responses, and alterations in the normal pattern of *c-fos* can lead to oncogenesis. Given the prominence of *c-fos* as an early response gene, apparent over-expression and prolonged lifetime of *c-fos*, as may be caused by an inhibitor of the ubiquitin-mediated degradation of *c-fos*, might sufficiently unbalance the cell-cycle and cause cell death. Alternatively, such inhibitors can be used to mimic the effects of an external stimulus on the cell, such as treatment with a cytokine.

II. Ubiquitin Conjugating Reactions

Assays which approximate the ubiquitination of target regulatory proteins in vertebrate cells, particularly mammalian cells, can be generated in many different forms, and include assays based on cell-free systems, e.g. purified proteins or cell lysates, as well as cell-based assays which utilize intact cells. Assays as described herein can be used in conjunction with the subject MDC complexes to generate a ubiquitin-conjugating system for detecting agents able to inhibit particular MDC-dependent ubiquitination of cellular or viral regulatory proteins. Such inhibitors can be used, for example, in the treatment of proliferative and/or differentiative disorders, to modulate apoptosis, and in the treatment of viral infections.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays of the present invention which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins or with lysates, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the *in vitro* system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with other proteins or change in enzymatic properties of the molecular target. Accordingly, potential inhibitors of MDC-dependent ubiquitination of a target protein can be detected in a cell-free assay generated by constitution of a functional ubiquitin conjugating system (including a CDC27/CDC16 complex) in a cell lysate, such as generated by charging a ubiquitin-depleted reticulocyte lysate (Hershko et al. (1983) *J Biol Chem* 258:8206-6214) with one or more of a ubiquitin-conjugating enzyme, an E1 enzyme, a mitotic destruction complex, ubiquitin, and/or a substrate for MDC-dependent ubiquitination, such as a B-type cyclin. In an alternate format, the assay can be derived as a reconstituted

protein mixture which, as described below, offers a number of benefits over lysate-based assays.

In an illustrative embodiment of the present assay, the ubiquitin-conjugating system comprises a reconstituted protein mixture of at least semi-purified proteins, and even more preferably of purified proteins. The reconstituted protein mixture is derived from preparations of the regulatory protein and ubiquitin under conditions which drive the conjugation of the two molecules. For instance, the mixture can include a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), an MDC comprising CDC27 and CDC16, and a nucleotide triphosphate (e.g. ATP). Alternatively, the E1 enzyme, the ubiquitin, and the nucleotide triphosphate can be substituted in the system with a pre-activated ubiquitin in the form of an E1:Ub conjugate. Likewise, a pre-activated ubiquitin can instead comprise an E2:Ub conjugate.

In preferred embodiments, the purified protein mixture substantially lacks any proteolytic activity which would degrade the target protein and/or components of the ubiquitin conjugating system. For instance, the reconstituted system can be generated to have less than 10% of the proteolytic activity associated with a typical reticulocyte lysate, and preferably no more than 5%, and most preferably less than 2%. Alternatively, the mixture can be generated to include, either from the onset of ubiquitination or from some point after ubiquitin conjugation of the regulatory protein, a ubiquitin-dependent proteolytic activity, such as a purified proteasome complex, that is present in the mixture at measured amounts.

In general, the use of reconstituted protein mixtures will be preferred among cell-free embodiments of the subject assay because they allow more careful control of the reaction conditions in the ubiquitin-conjugating system. Moreover, the system can be derived to favor discovery of inhibitors of particular steps of the ubiquitination process, especially the MDC-dependent steps. For instance, as set out above, a reconstituted protein assay can be generated which does not facilitate degradation of the ubiquitinated protein, and which utilizes a precharged E2:Ub conjugate. The level of ubiquitin-conjugated protein, which is dependent on a CDC27/CDC16 complex can easily be measured directly in such a system, both in the presence and absence of a candidate agent, thereby enhancing the ability to detect an inhibitor of the CDC27/CDC16-dependent step. Alternatively, the Ub-conjugating system can be allowed to develop a steady state level of regulatory protein:Ub conjugates in the absence of a proteolytic activity, but then shifted to a degradative system by addition of purified Ub-dependent proteases. Such degradative systems would be amenable to identifying proteasome inhibitors.

Moreover, in the subject method, ubiquitin conjugating systems derived from purified proteins hold a number of significant advantages over cell lysate or wheat germ extract based assays (collectively referred to hereinafter as "lysates"). especially "whole" lysates. Unlike

the reconstituted protein system, the synthesis and destruction of the target protein cannot be readily controlled for in lysate-based assays. Without knowledge of particular kinetic parameters for Ub-independent and Ub-dependent degradation of the target protein in the lysate, discerning between the two pathways can be extremely difficult. Measuring these parameters, if at all possible, is further made tedious by the fact that cell lysates tend to be inconsistent from batch to batch, with potentially significant variation between preparations. Evaluation of a potential inhibitor using a lysate system is also complicated in those circumstances where the lysate is charged with mRNA encoding the target protein, as such lysates may continue to synthesize the protein during the assay, and will do so at unpredictable rates.

Accordingly, knowledge of the concentration of each component of the ubiquitin conjugation pathway can be required for each lysate batch, along with the degradative kinetic data, in order to determine the necessary time course and calculate the sensitivity of experiments performed from one lysate preparation to the next.

Furthermore, the lysate system can be unsatisfactory where the target protein itself has a relatively short half-life, especially if due to degradative processes other than the ubiquitin-mediated pathway to which an inhibitor is sought. However, as described, this effect can be mitigated by the use of protease inhibitors such as PMSF or TPCK to inhibit proteolysis of the target protein, though broad-spectrum inhibitors will knock out both ubiquitin-dependent and independent proteolysis.

Moreover, many of the disadvantages of whole cell lysates described above can be overcome by the use of semi-purified cell extracts and/or lysates that have been charged with one or more components of a ubiquitin-conjugation pathway. For example, by selective removal of cell lysate components which interfere with ubiquitination assays, an assay may be feasible in a cell extract even without further purification. Such an approach makes possible rapid and inexpensive development of assay systems suitable for use with ubiquitination assays.

Thus, in another aspect of the subject invention, the ubiquitin-conjugating system comprises a semi-purified cell extract. For instance, as described in the examples below, semi-purified cell extracts can be produced by treatment of cell lysates by a variety of techniques. For example, chromatographic methods and the like can be used to partially purify at least one component of the cell lysate. Likewise, semi-purified cell lysates may be prepared by treatment of a cell lysate to selectively remove a component of the lysate, for example, by immunoprecipitation (see, e.g., Example 6, *infra*). Many other methods for the preparation of semi-purified cell extracts by the selective removal or enrichment of components of a cell lysate will be evident to the skilled artisan.

In yet another embodiment of the subject assay, a cell lysate can be charged with certain of the components of an MDC-dependent ubiquitination system. For example, in addition to inhibitors or potentiators of ubiquitination, a semi-purified cell extract can be charged with UBC4, UBC5, CDC27, CDC16, cyclin B and the like. Likewise, lysates can be generated from cells recombinantly manipulated to produce, for example, a labeled component to the assay, such as a myc-labeled ubiquitin or a GST-cyclin fusion protein.

Ubiquitination of the target regulatory protein via an *in vitro* ubiquitin-conjugating system, in the presence and absence of a candidate inhibitor, can be accomplished in any vessel suitable for containing the reactants. Examples include microtitre plates, test tubes, and micro-centrifuge tubes. In certain embodiments of the present assay, the *in vitro* assay system is generated to lack the ability to degrade the ubiquitinated target protein. In such an embodiment, a wide range of detection means can be practiced to score for the presence of the ubiquitinated protein.

In one embodiment of the present assay, the products of a non-degradative ubiquitin-conjugating system are separated by gel electrophoresis, and the level of ubiquitinated target protein assessed, using standard electrophoresis protocols, e.g., by detecting an increase in molecular weight of the target protein that corresponds to the addition of one or more ubiquitin chains. For example, one or both of the target protein and ubiquitin can be labeled with a radioisotope such as ^{35}S , ^{14}C , or ^3H , and the isotopically labeled protein bands quantified by autoradiographic techniques. Standardization of the assay samples can be accomplished, for instance, by adding known quantities of labeled proteins which are not themselves subject to ubiquitination or degradation under the conditions which the assay is performed. Similarly, other means of detecting electrophoretically separated proteins can be employed to quantify the level of ubiquitination of the regulatory protein, including immunoblot analysis using antibodies specific for either the regulatory protein or ubiquitin, or derivatives thereof. As described below, the antibody can be replaced with another molecule able to bind one of either the regulatory protein or ubiquitin. By way of illustration, one embodiment of the present assay comprises the use of biotinylated ubiquitin in the conjugating system. The biotin label is detected in a gel during a subsequent detection step by contacting the electrophoretic products (or a blot thereof) with a streptavidin-conjugated label, such as a streptavidin linked fluorochrome or enzyme, which can be readily detected by conventional techniques. Moreover, where a reconstituted protein mixture is used (rather than a lysate) as the conjugating system, it may be possible to simply detect the regulatory protein and ubiquitin conjugates in the gel by standard staining protocols, including coomassie blue and silver staining.

In another embodiment, an immunoassay or similar binding assay, is used to detect and quantify the level of ubiquitinated regulatory protein produced in the ubiquitin-conjugating

system. Many different immunoassay techniques are amenable for such use and can be employed to detect and quantitate the regulatory protein:Ub conjugates. For example, the wells of a microtitre plate (or other suitable solid phase) can be coated with an antibody which specifically binds one of either the regulatory protein or ubiquitin. After incubation of the ubiquitin-conjugated system with and without the candidate agent, the products are contacted with the matrix bound antibody, unbound material removed by washing, and ubiquitin conjugates of the regulatory protein specifically detected. To illustrate, if an antibody which binds the regulatory protein is used to sequester the protein on the matrix, then a detectable anti-ubiquitin antibody can be used to score for the presence of ubiquitinated regulatory protein on the matrix.

However, it will be clear to those skilled in the art that the use of antibodies in these binding assays is merely illustrative of binding molecules in general, and that the antibodies are readily substituted in the assay with any suitable molecule that can specifically detect one of either the regulatory protein or the ubiquitin. As described below, a biotin-derivative of ubiquitin can be used, and streptavidin (or avidin) employed to bind the biotinylated ubiquitin. In an illustrative embodiment, wells of a microtitre plate are coated with streptavidin and contacted with the developed ubiquitin-conjugating system under conditions wherein the biotinylated ubiquitin binds to and is sequestered in the wells. Unbound material is washed from the wells, and the level of regulatory protein (bound to the matrix via a conjugated ubiquitin moiety) is detected in each well. Alternatively, the microtitre plate wells can be coated with an antibody (or other binding molecule) which binds and sequesters the regulatory protein on the solid support, and detection of ubiquitinated conjugates of the matrix-bound regulatory protein are subsequently carried out using a detectable streptavidin derivative, such as an alkaline phosphatase/streptavidin complex.

In similar fashion, epitope-tagged ubiquitin, such as myc-ub (see Ellison *et al.* (1991) *J. Biol. Chem.* 266:21150-21157; ubiquitin which includes a 10-residue sequence encoding a protein of c-myc) can be used in conjunction with antibodies to the epitope tag. A major advantage of using such an epitope-tagged ubiquitin approach for detecting Ub:protein conjugates is the ability of an N-terminal tag sequences to inhibit ubiquitin-mediated proteolysis of the conjugated regulatory protein.

Other ubiquitin derivatives include detectable labels which do not interfere greatly with the conjugation of ubiquitin to the regulatory protein. Such detectable labels can include fluorescently-labeled (e.g. FITC) or enzymatically-labeled ubiquitin fusion proteins. These derivatives can be produced by chemical cross-linking, or, where the label is a protein, by generation of a fusion protein. Several labeled ubiquitin derivatives are commercially available.

Likewise, other binding molecules can be employed in place of the antibodies that bind the regulatory protein. For example, the regulatory protein can be generated as a glutathione-S-transferase (GST) fusion protein. As a practical matter, such GST fusion protein can enable easy purification of the regulatory protein in the preparation of components of the ubiquitin-conjugating system (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* (NY: John Wiley & Sons, 1991); Smith *et al.* (1988) *Gene* 67:31; and Kaelin *et al.* (1992) *Cell* 70:351). Moreover, glutathione derivatized matrices (e.g. glutathione-sepharose or glutathione-coated microtitre plates) can be used to sequester free and ubiquitinated forms of the regulatory protein from the ubiquitin-conjugating system, and the level of ubiquitin immobilized can be measured as described. Likewise, where the matrix is generated to bind ubiquitin, the level of sequestered GST-regulatory protein can be detected using agents which bind to the GST moiety (such as anti-GST antibodies), or, alternatively, using agents which are enzymatically acted upon by GST to produce detectable products (e.g. 1-chloro-2,4-dinitrobenzene; Habig *et al.* (1974) *J Biol Chem* 249:7130). Similarly, other fusion proteins involving the regulatory protein and an enzymatic activity are contemplated by the present method. For example, fusion proteins containing β -galactosidase or luciferase, to name but a few, can be employed as labels to determine the amount of regulatory protein sequestered on a matrix by virtue of a conjugated ubiquitin chain.

Moreover, such enzymatic fusion proteins can be used to detect and quantitate ubiquitinated regulatory protein in a heterogeneous assay, e.g., one which does not require separation of the components of the conjugating system. For example, ubiquitin conjugating systems can be generated to have a ubiquitin-dependent protease which degrades the regulatory protein. The enzymatic activity of undegraded fusion protein provides a detectable signal, in the presence of substrate, for effectively measuring the level of the regulatory protein ubiquitination. Similarly, in a non-degradative conjugating system, ubiquitination of the regulatory protein portion of the fusion protein can allosterically influence the enzymatic activity associated with the fusion the protein and thereby provides a means for monitoring the level of ubiquitin conjugation.

In binding assay-type detection steps such as set out above, the choice of which of either the regulatory protein or ubiquitin should be specifically sequestered on the matrix will depend on a number of factors, including the relative abundance of both components in the conjugating system. For instance, where the reaction conditions of the ubiquitin conjugating system provide ubiquitin at a concentration far in excess of the level of the regulatory protein. (e.g., one order of magnitude or greater) sequestering the ubiquitin and detecting the amount of regulatory protein bound with the ubiquitin can provide less dynamic range to the detection step of the present method than the converse embodiment of sequestering the regulatory protein and detecting ubiquitin conjugates from the total regulatory protein bound

to the matrix. That is, where ubiquitin is provided in great excess relative to the regulatory protein, the percentage of ubiquitin conjugated regulatory protein in the total ubiquitin bound to the matrix can be small enough that any diminishment in ubiquitination caused by an inhibitor can be made difficult to detect by the fact that, for example, the statistical error of the system (e.g. the noise) can be a significant portion of the measured change in concentration of bound regulatory protein. Furthermore, it is clear that manipulating the reaction conditions and reactant concentrations in the ubiquitin-conjugating system can be carried out to provide, at the detection step, greater sensitivity by ensuring that a strong ubiquitinated protein signal exists in the absence of any inhibitor.

In still further embodiments of the present invention, the ubiquitin-conjugating system is generated in whole cells, taking advantage of cell culture techniques to support the subject assay. For example, as described below, the ubiquitin-conjugating system (including the target protein and detection means) can be constituted in a eukaryotic cell culture system, including mammalian and yeast cells. Advantages to generating the subject assay in an intact cell include the ability to detect inhibitors which are functional in an environment more closely approximating that which therapeutic use of the inhibitor would require, including the ability of the agent to gain entry into the cell. Furthermore, certain of the *in vivo* embodiments of the assay, such as examples given below, are amenable to high through-put analysis of candidate agents.

The components of the ubiquitin-conjugating system, including the regulatory protein, can be endogenous to the cell selected to support the assay. Alternatively, some or all of the components can be derived from exogenous sources. For instance, a recombinantly produced E2 enzyme, such as UBC4, or recombinantly produced components of an MDC, such as CDC27, can be expressed in the cell by recombinant techniques (such as through the use of an expression vector), as well as by microinjecting the proteins themselves or mRNA encoding the protein.

In any case, the cell is ultimately manipulated after incubation with a candidate inhibitor in order to facilitate detection of ubiquitination or ubiquitin-mediated degradation of the regulatory protein. As described above for assays performed in reconstituted protein mixtures or lysates, the effectiveness of a candidate inhibitor can be assessed by measuring direct characteristics of the regulatory protein, such as shifts in molecular weight by electrophoretic means or detection in a binding assay. For these embodiments, the cell will typically be lysed at the end of incubation with the candidate agent, and the lysate manipulated in a detection step in much the same manner as might be the reconstituted protein mixture or lysate.

Indirect measurement of ubiquitination of the target protein can also be accomplished by detecting a biological activity associated with the regulatory protein that is either

attenuated by ubiquitin-conjugation or destroyed along with the regulatory protein by ubiquitin-dependent proteolytic processes. As set out above, the use of fusion proteins comprising the regulatory protein and an enzymatic activity are representative embodiments of the subject assay in which the detection means relies on indirect measurement of ubiquitination of the regulatory protein by quantitating an associated enzymatic activity.

Where the regulatory protein has a relatively short half-life due to ubiquitin-dependent or independent degradation in the cell, preferred embodiments of the assay either do not require cell lysis, or, alternatively, generate a longer lived detection signal that is independent of the regulatory protein's fate after lysis of the cell. With respect to the latter embodiment, the detection means can comprise, for example, a reporter gene construct which includes a positive transcriptional regulatory element that binds and is responsive to the regulatory protein. For instance, where the regulatory protein of interest is p53, p53 responsive elements can be used to construct the reporter gene producing a gene product which is a detectable label, such as luciferase or β -galactosidase (see, for example, U.S. Patent 5,362,623), and which is produced in the intact cell. The label can be measured in a subsequent lysate of the cell. However, the lysis step is preferably avoided, and providing a step of lysing the cell to measure the label will typically only be employed where detection of the label cannot be accomplished in whole cells.

Where the regulatory protein does not itself possess DNA-binding ability, it can be arranged as part of an interaction trap assay designed for detecting inhibitors of the MDC-dependent destruction of the protein (see, for example, U.S. Patent No: 5,283,317; PCT publication WO94/10300; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J Biol Chem* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; and Iwabuchi et al. (1993) *Oncogene* 8:1693-1696). In an illustrative embodiment, *Saccharomyces cerevisiae* YPB2 cells are transformed simultaneously with a plasmid encoding a GAL4db-CDC2 (where CDC2 is a human CDC2) fusion and with a plasmid encoding the GAL4ad domain fused to human cyclin B. Moreover, the strain is transformed such that the GAL4-responsive promoter drives expression of a phenotypic marker. For example, the ability to grow in the absence of histidine depends on the expression of the HIS3 gene if it is under control of a GAL4-responsive promoter and, therefore, indicates that a functional GAL4 activator has been reconstituted through the interaction of the human CDC2 and cyclin B fusion proteins. The strain is further manipulated to be "humanized" with respect to MDC-mediated ubiquitination of the cyclin B fusion protein. For example, conditional inactivation of the yeast UBC4, with concomitant expression of the human UBC4 enzyme, or alternatively, replacement of the yeast CDC27 and/or CDC16 genes with the human homologs, provides a humanized system whereby the cyclin B fusion protein can be ubiquitinated by a mechanism which approximate the MDC-dependent ubiquitination which occurs in vertebrate cells.

Thus, agents able to inhibit the ubiquitination of the cyclin B fusion protein will result in yeast cells able to growth in the absence of histidine, as the GAL4db-CDC2 and GAL4ad-cyclin fusion proteins will be able to interact and cause expression of the HIS3 gene. Alternatively, the agents which do not effect the ubiquitination of the cyclin B fusion protein will result in cells unable to grow in the absence of histidine as the GAL4ad-cyclin fusion protein will be degraded or otherwise prevented from interacting with the GAL4db-CDC2 protein.

III. Competitive binding assays

Furthermore, drug screening assays can be generated which do not measure ubiquitination *per se*, but rather detect inhibitory agents on the basis of their ability to interfere with binding of one of the proteins involved in the MDC-dependent ubiquitin conjugation pathway. In an exemplary binding assay, the compound of interest is contacted with a mixture generated from an isolated and purified E2 protein, such as UBC4, and an mitotic destruction complex, such as comprising the CDC27 and CDC16 proteins. Alternatively, the MDC and cyclin are combined in the presence and absence of test agents so as to provide a competitive binding assay which detects agents able to compete with the cyclin for binding to the MDC. Detection and quantification of complexes between the MDC and either UBC4 or the cyclin provides a means for determining the compound's efficacy at inhibiting (or potentiating) complex formation between the MDC and other components of the MDC-dependent ubiquitin pathway. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, isolated and purified UBC4 or cyclin is added to a composition containing the MDC, and the formation of complexes is quantitated in the absence of the test compound.

Complex formation between the E2 protein or regulatory protein and the MDC may be detected by a variety of techniques, many of which are effectively described above. For instance, modulation in the formation of complexes can be quantitated using, for example, detectably labeled proteins (e.g. radiolabelled, fluorescently labelled, or enzymatically labelled). by immunoassay, or by chromatographic detection.

Typically, it will be desirable to immobilize either the E2, the regulatory protein or a component of the MDC, such as the CDC27 protein, to facilitate separation of complexes from uncomplexed forms of one of the proteins, as well as to accommodate automation of the assay. In an illustrative embodiment, a fusion protein can be provided which adds a domain that permits the protein to be bound to an insoluble matrix. For example, GST/cyclin fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the MDC. e.g.

containing ^{35}S -labeled proteins, and the test compound and incubated under conditions conducive to complex formation. Following incubation, the beads are washed to remove any unbound MDC, and the matrix bead-bound radiolabel determined directly (e.g. beads placed in scintillant), or in the supernatant after the complexes are dissociated, e.g. when microtitre plate is used. Alternatively, after washing away unbound protein, the complexes can be dissociated from the matrix, separated by SDS-PAGE gel, and the level of, for example, CDC27 or CDC16 protein found in the matrix-bound fraction quantitated from the gel using standard electrophoretic techniques.

In similar fashion, the interaction trap described above can be provided to detect agents able to modulate the binding of CDC27 or CDC16 or another component of the MDC to an E2 or a regulatory protein.

With respect to sources for the proteins constituting the ubiquitin-conjugating system and competitive binding assays, particularly those used to generate the reconstituted protein mixture or other embodiments requiring recombinant or purified preparations of proteins, many species of the enzymes and other proteins involved in ubiquitination have been identified, and in a significant number of instances, have been cloned so that recombinant sources exist. Isolation of enzymes of the ubiquitin-conjugating system has been greatly assisted by "covalent" ubiquitin-affinity chromatography (Crehanover *et al.* (1982) *J. Biol. Chem.* 257:2537-2542; and Pickart *et al.* (1985) *J. Biol. Chem.* 260:1573-1581). This method takes advantage of the fact that the E1 enzyme is capable of forming a thiol ester with immobilized ubiquitin (e.g. ubiquitin-sepharase) in the presence of ATP. As described in Example 1, such a protocol can be used to purify recombinantly expressed E1. Moreover, E1 enzymes bound to the immobilized ubiquitin can be exchanged with E2 enzymes, such as UBC4. Thus, both E1 and E2 enzymes can be specifically purified on such columns, and can be recovered after elution with, for example, dithiothreitol. Under appropriate elution conditions, ubiquitin activated E1 or E2 complexes can be isolated and, as described herein, used in the present assay to increase the selectivity of the assay for an inhibitor of a particular step of ubiquitin-conjugation. Moreover, with minor changes, this protocol can be used to isolate E1:Ub or E2:Ub conjugates (e.g. activated ubiquitin conjugates) for use in the reconstituted protein mixture.

Identification of enzymes involved in the ubiquitin pathway from different sources have facilitated the cloning of corresponding genes. For instance, genes encoding E1 enzymes have been cloned from various organisms (see, for example, Adams *et al.* (1992) *Nature* 355:632-634; Handley *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:258-262; Handley *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7456; Hatfield *et al.* (1990) *J. Biol. Chem.* 265:15813-15817; Kay *et al.* (1991) *Nature* 354:486-489; McGrath *et al.* (1991) *EMBO J* 10:227-236; Mitchell *et al.* (1991) *Nature* 354:483-486; and Zacksenhaus *et al.* (1990) *EMBO J* 9:2923-

2929). The sequences of various cloned E1 enzymes predict proteins of roughly 100kd, and which contain the nucleotide-binding consensus sequence Gly-Xaa-Gly-Xaa-Xaa-Gly (McGrath *et al.* (1991) *EMBO J* 10:227-236).

In contrast to the ubiquitin-activating enzyme (E1), where it is generally believed that there are relatively few different species of the enzyme in a given cell, eukaryotic cells can express a large and diverse array of E2 enzymes. This remarkable variety of E2 enzymes, along with experimental evidence, has implicated the E2 enzyme as the principle determinant of substrate selectivity in the ubiquitin system. The E2 enzyme, as set out above, catalyzes isopeptide bond formation between ubiquitin and substrate proteins, either with or without the aid of a substrate recognition factor (ubiquitin-ligase protein; E3). So far, several major species of E2 enzymes have been identified and purified by ubiquitin-affinity chromatography of extracts from rabbit reticulocytes (Pickart *et al.* (1985) *J Biol Chem* 260:1573-1581), yeast (Jentsch *et al.* (1987) *Nature* 329:131-134), and wheat (Sullivan *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:9861-9865). Furthermore, many genes encoding E2 enzymes have been cloned and characterized with several human (and other mammalian) E2 enzymes having been cloned. For example, the cloning of human UBC5 (GenBank X78140) is described at Scheffner *et al.* (1994) *PNAS* 91:8797-8801; the cloning of human UBC2 (GenBank Z29328) is described at Kaiser *et al.* (1994); *J. Biol. Chem* 269:8797-8802; the cloning of human UBC1 is described at Kaiser *et al.* (1994) *FEBS Lett* 350:1-4; the cloning of other human ubiquitin conjugating enzymes, such as GenBank X53251 and M74525, are taught by Schneider *et al.* (1990) *Embo J.* 9:1431-1435 and Koken *et al.* (1991) *PNAS* 88:8865-8869, respectively. Still other human UBC's are described in the literature. (Koken *et al.* (1992) *Genomics* 12:447-453; Koken *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:8865-8869; and Schneider *et al.* (1990) *EMBO J* 9:1431-1435).

The regulatory protein provided in the subject assay can be derived by purification from a cell in which it is exogenously expressed, or from a recombinant source of the protein. For example, cDNA clones are available for a number of regulatory proteins, including cyclin B (Pines *et al.* (1989) *Cell* 58:833-846); p53 (Oren *et al.* (1983) *EMBO J* 2:1633-1639); c-myc (Hann *et al.* (1988) *Cell* 52:185-195); N-myc (Curran *et al.* (1987) *Oncogene* 2:79-84); MAT α 2 (Hochstrasser *et al.* (1990) *Cell* 61:697-708); and E1A (Salvick *et al.* (1988) *EMBO J* 7:3171-3180).

In each instance where a recombinant source of a protein is used in the subject assay, the manipulation of the gene encoding the protein and the subsequent expression of the protein can be carried out by standard molecular biological techniques. Ligating the polynucleotide sequence encoding the recombinant protein into a gene construct, such as an expression vector, and transforming or transfecting into host cells, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures used in

producing other well-known proteins, e.g. insulin, interferons, human growth hormone, IL-1, IL-2, and the like. Similar procedures, or obvious modifications thereof, can be employed to prepare and purify recombinant proteins of the ubiquitin-conjugating system by microbial means or tissue-culture technology for use in the subject assay.

5 The recombinant protein (e.g. E1, E2, CDC27, CDC16, the regulatory protein, etc.) can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vehicles for production of recombinant proteins include plasmids and other vectors. For instance, suitable vectors for the expression of these proteins include plasmids of the types: pBR322-derived
10 plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see for example
15 Broach *et al.* (1983) in *Experimental Manipulation of Gene Expression*, ed M. Inouye Academic Press, p. 83+). These vectors can replicate in *E. coli* due the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication determinant of the yeast 2 micron plasmid. In addition, drug resistance markers such as ampicillin can be used.

The preferred mammalian expression vectors contain both prokaryotic sequences to
20 facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pH β APr-1-neo, EBO-pcD-XN, pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with
25 sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host
30 organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press:1989) Chapters 16 and 17.

In some instances, as described below in Example 1, it may be desirable to express
35 the recombinant protein by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393

and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

5 In preferred embodiments, the expression vectors used to produce the recombinant proteins of the present invention are chosen to include at least one selectable marker for each cell line in which the vector is to be replicated or expressed. For instance, the vectors can be derived with sequences conferring resistance to ampicillin, chloramphenicol or kanomycin to facilitate amplification in *E. coli*. For selection in mammalian cells, such markers as the mammalian expressible *E. coli ecogpt* gene -which codes for a xanthine-guanine phosphoribosyl transferase (XGPRT) and allows selection of transfected HPRT⁻ mammalian
10 cells with mycophenolic acid- can be utilized.

Furthermore, the recombinant protein can be encoded by a fusion gene created to have additional sequences coding for a polypeptide portion of a fusion protein which would facilitate its purification. For instance, Example 1 describes a fusion gene coding for a purification leader sequence comprising a poly-(His)/enterokinase cleavage site sequence at
15 the N-terminus of the desired portion the protein, thereby enabling purification of the expressed fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase (e.g., see Hochuli *et al.* 1987 *J. Chromatography* 411:177; and Janknecht *et al.* *Proc. Natl. Acad. Sci. USA* 88:8972).

20 ***Exemplification***

The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

25 **Example 1**

Ubiquitin can be obtained from commercial sources, and the remaining protein components of the reconstituted protein system cloned from, for example, HeLa cells (ATCC CCL2). Briefly, polyadenylated RNA is isolated from cultured HeLa cells and first strand cDNA is prepared following standard protocols (c.f., Chomczynski U.S. Patent No.
30 4,843,155; and Sambrook *et al. Molecular Cloning: A Laboratory Manual*, CSHL Press. Cold Spring Harbor, NY (1989)). PCR primers, designed to amplify DNA sequences encoding each of the component proteins, as well as provide convenient restriction sites to the PCR products, are used to isolate coding sequences for a human E1, human cyclin B, CDC27, CDC16, and UBC4, which are subsequently ligated into a pBluescript II KS+ phagemid (pKS+, Stratagene catalog no. 212207) for further manipulation. As described
35 below, each of the component proteins genes are subsequently sub-cloned from pKS+ into

other expression vectors to generate gene constructs for producing the recombinant proteins in either bacterial or insect cells. In some instances, the recombinant proteins can be provided with exogenous sequences to produce fusion proteins, where the additional sequences of the fusion protein facilitate its purification.

5 i) *Human E1*

Utilizing the primers 5'-(GC)₃AAGCTTATGTCCAGCTCGCCGCTGTCCAAG-3' and 5'-(GC)₃GGATCCTCAGCGGATGGTGTATCGGACATA-3', the coding sequence for a human E1 (SEQ ID No. 3) is amplified from a HeLa cell cDNA library. The PCR amplification product containing the E1 coding sequences is purified and cut with HindIII and BamHI (restriction sites provided by the PCR primers), and ligated into the pKS+ phagemid. The resulting pKS-E1 construct is amplified in XL1-Blue Cells (Stratagen catalog no. 260268), and double stranded construct purified.

A Hind III/fill to BamHI fragments containing the E1 coding sequence is isolated from the pKS-E1 construct, where "Hind III/fill" indicates that a Hind III overhang generated in the fragment is filled to form a blunt-end using Klenow and dNTPs. The E1 gene fragment is purified by agarose gel separation, and ligated into the baculovirus vector pVL1393 (Invitrogen catalog no. V1392-20) previously cut with SmaI and BglII. The pVL1393-E1 construct is used to transfect *spodoptera frugiperda* (Sf9) cells (ATCC CRL 1711), and the cells maintained in insect cell culture media (Grace's *Antheraea* medium) supplemented with 10% FBS, lactal bumin hydrolysate, TC yeastolate and glutamate (Invitrogen catalog no. B823) following standard protocols (Invitrogen product guide; Summers and Smith (1987); *Texas Agricultural Experiment Station Bulletin No. 1555*, College Station, Texas; Luckow *et al.* (1988) *Bio/technology* 6:47-55; and Miller *et al.*, in *Genetic Engineering, Vol. 8* (Setlow and Hollaender, eds) pp. 277-298, Plenum, New York). Transfected cells are grown until the cells begin to lose their adherence to the culture plate surface, at which time the cells are harvested, collected by centrifugation, and lysed. The lysate is clarified by centrifugation to remove the cell wall debris, and the E1 containing lysate is applied to a sepharose-ubiquitin column (Hershko *et al.* (1983) *J. Biol. Chem.* 257:2537-2542) in the presence of ATP (e.g. 5m MATP, 10mM MgCl₂, and 0.2 mM clithiothreitol, 50mM Tris-HCl (pH 7.2)). The column is washed several times with this buffer, and the E1 protein eluted with the following solutions: 1M KCl containing 50mM Tris-HCl, pH7.2 (KCl eluate); the above Tris buffer, to remove salt; and finally 2mM ATP and 0.04 mM sodium pyrophosphate in the above Tri buffer. The E1-containing eluate can be concentrated, as well as placed in new buffer solution, by centrifuge ultrafiltration with CentriPrep or Centricon membranes (Amicon Corp., MA). Alternatively, the ubiquitin-immoblized E1 can be used, as described below, in the purification of E2 enzymes.

ii) *Human UBC4*

The UBC4 ubiquitin-conjugating enzyme (SEQ ID No: 4) is amplified and cloned from a HeLa cell cDNA library using the PCR primer sets 5'-(GC)₃AAGCTTTAYGARGGWGGWGT-YTTYTT-3', 5'-(GC)₃GAATTCACNGCRTAYT-TYTTNGTCCCCAYTC-3' and 5'-(GC)₃AAGCTTCCNGTNGGNGAYTTRTTYCAYTG-GCA-3', 5'-(GC)₃GAATTCATNGTNARNGC-NGGCGACCA-3', and cloned into pBluescript II pKS+ as a Hind III-EcoRI fragment. After further amplification, the pKS-UBC4 construct is cut with XhoI and EcoRI, and the fragment containing the UBC4 coding sequence sub-cloned into a pGEX vector (Pharmacia catalog no. PGEX-4T-2) previously digested with SalI and EcoRI. The resulting pGEX-UBC4 construct encodes a glutathione-S-transferase (GST)/E2 fusion, and is introduced into *E.coli* by transformation, with the transformants grown in liquid media (LB) in the presence of IPTG. Purification of GST/E2 fusion protein is by standard protocols (*Current Protocols in Molecular Biology*, eds. Ausubel *et al.* (NY:John Wiley & Sons, 1991); Pharmacia instruction booklet (for catalog no. 27-4570)) using a glutathione-sepharose column (Pharmacia catalog no. 27-4570). Treatment with thrombin removes the GST domain from the fusion protein.

Alternatively, the UBC4 coding sequence can be excised from the pKS-UBC4 construct as a HindIII-EcoRI fragment and ligated into pVL1393 cut with Sma I and Eco I. The E2 protein is produced in Sf9 cells, as described above, and purified on a sepharose-ubiquitin:E1 column. As above, a clarified lysate of the E2-producing insect cells, adjusted to 50mM Tris-HCl (pH 7.2), 5mM ATP, 10mM MgCl₂, and 0.2 mM dithiothreitol, is applied to the ub:E1 column, washed, then eluted to remove any remaining ub:E1 (e.g. E2 will be exchanged for E1 on the column). UBC4 is then eluted from the column by washing with Tris buffer containing dithiothreitol.

iii) Human cyclin B1

Following similar protocols as described above, the human cyclin B1 gene can be cloned into the appropriate expression vector for recombinant production of the protein (see, for example, Pines *et al.* (1989) *Cell* 58:833-846). For instance, utilizing the primers 5'-(GC)₃GGATCCATGGCGCTCCGAGTC and 5'-(GC)₃CTTAAGCTACGTACGGTGTC, the human cyclin B1 coding sequence can be amplified by PCR, cut with BamHI and EcoRI, and ligated into pGEX-4T-2 (Pharmacia) to produce a GST-cyclin B fusion protein that can be purified according to the manufacturer's protocols.

iv) Human CDC27

The human CDC27 gene (SEQ ID NO: 2) can be manipulated, as above, to provide various recombinant forms of the protein, with expression in both prokaryotic and eukaryotic systems. For instance, the coding sequence of human CDC27 can be amplified from a human cDNA library with the PCR primers 5'-(GC)₃ GGATCCATGACGGTGCTG and 5'-(GC)₃

TTCGAAAAATTCATCACT, the amplified product cut with BamHI and HindIII, and that fragment cloned into the pRSET vector (Invitrogen). The pRSET-CDC27 construct is used to transfect JM109 *E.coli*, the resulting cultures lysed, and the poly (His)-tagged CDC27 purified on a ProBond (Invitrogen) Ni²⁺-sepharose column according to the manufacturer's directions. The poly (His) sequence can be removed by treatment with enterokinase.

v) *Human CDC16*

A recombinant form of the human CDC16 protein can be generated by first cloning the CDC16 cDNA from the expressed sequence tag clone of ATCC deposit 85882 (see GenBank accessions T09436 and U18291). The coding sequence for the human CDC16 can be provided in any of a number of expression vectors to produce the recombinant protein as desired.

Alternatively, CDC27, such as the poly(His)-CDC27 described above, can be used to isolate CDC16 and other components of the MDC from cell lysates by affinity chromatography.

vi) *Ubiquitin*

Ubiquitin is available from commercial sources (Bovine ubiquitin, Sigma catalog no. 6253; yeast ubiquitin, Sigma catalog no. 2129). Various modified forms of ubiquitin are also available as for example, fluorescein-labeled ubiquitin (Sigma catalog no. U5504), and horseradish-peroxidase labeled ubiquitin (Sigma catalog no. U9879). Biotinylated ubiquitin can be prepared from biotin-NHS (N-hydroxy-succinimide ester) using well-known techniques (biotinylation kit; Pierce catalog no. 214206, 203188 (6 atom spacer), or 203114 (14 atom spacer)).

vii) *Additional Reagents*

For generating certain of the detection means as described herein, some of the following reagents can be employed: polyclonal sera to ubiquitin (Sigma catalog no. U5379); labeled antibodies to biotin (Sigma catalog nos. A4541 (peroxidase conjugated) and F6762 (FITC conjugated)); labeled avidin (Sigma catalog nos. A7294, E2636 (peroxidase conjugated) and A2050, E2761 (FITC conjugated)); streptavidin (Sigma catalog no. S3762 (FITC conjugated) and S5512 (peroxidase conjugated)); Streptavidin-coated beads (Sigma catalog no. 400996; Pierce catalog no. 20347G); Streptavidin-coated 96 well microtiter plates (Pierce catalog no. 15124); Maleic anhydride-activated polystyrene 96 well plates (Pierce catalog no. 15110); and antibody to human cyclin B (PharMingen catalog).

Example 2

To generate the ubiquitin-conjugating system comprising a reconstituted protein mixture, portions of each of the preparations of purified components (described above), along with ubiquitin, are mixed together in a conjugation buffer comprising 50mM Tris-HCl (pH7.4), 5mM MgCl₂, 2mM ATP, 0.1 mM DTT, and 5 μM ubiquitin. In a typical reaction, E1, UBC4, the target protein (cyclin B), and the MDC complex (either purified as described in Example 6, or reconstituted as above), are added to the conjugation buffer at approximately 100ng each in a final reaction volume of 20-50μL. The reconstituted ubiquitin-conjugating system is incubated at 25°C for varying lengths of time (e.g. 0.5 to 30 minutes), in the presence of varying concentrations of a candidate agent (e.g. 0 to 50mM), and the reaction quenched with iodoacetate and/or arsenite. Where either pre-conjugated E1:Ub or UBC4:Ub is used to generate the mixture, the level of the conjugate in the reaction system can be increased to 5-10μM, and free ubiquitin left out of the conjugation buffer. The levels of cyclin:Ub conjugates in the presence and absence of a candidate agent can be determined as described herein, taking into account statistical significance (e.g. the error of the particular assay employed) and appropriate controls.

Example 3

³⁵S-labeled cyclin B, prepared by cell culture technique utilizing ³⁵S-methionine, is incubated with combined purified components of a ubiquitin conjugating system as described in Example 2, including biotinylated ubiquitin. The reaction is conducted in a 96 well microtitre plate and stopped with iodoacetate. The reaction mixture is transferred to the wells of a streptavidin-coated microtitre plate and incubated to capture the complex of biotinylated ubiquitin and cyclin B (free biotinylated ubiquitin will also compete for binding sites on the well). The wells are washed with buffer (e.g. phosphate-buffered saline, or conjugation buffer lacking ubiquitin and ATP) to remove uncomplexed cyclin. Ubiquitinated cyclin is detected by addition of scintillant to the well and counting in a scintillation instrument. Inhibition of the ubiquitin conjugation system by an added candidate agent is indicated by a reduced radioactive count

Example 4

Cyclin B1 is incubated with combined purified components of a ubiquitin conjugating system as described above, including biotinylated ubiquitin. The reaction is conducted in a 96 well microtitre plate and stopped with iodoacetate. The reaction mixture is transferred to the wells of a streptavidin coated microtitre plate and incubated to capture the complex of biotinylated ubiquitin and cyclin (free biotinylated ubiquitin will also compete for binding sites on the well). The wells are washed with buffer to remove uncomplexed cyclin. Next, the

ub:cyclin complexes captured on the plate are decorated with an antibody to cyclin B1. The wells are washed and binding of monoclonal antibody is detected by addition of peroxidase-conjugated antibody to mouse IgG (H+L) (Pierce catalog nos. 91430G and 91450G) and contacting with an appropriate substrate system, such as o-phenylenediamine dihydrochloride (Sigma catalog no. P9187).

Example 5

A glutathione S-transferase (GST)-cyclin B fusion product is incubated with combined purified components of a ubiquitin conjugating system, including biotinylated ubiquitin. The reaction is conducted in a 96 well microtitre plate and stopped with iodoacetate. The reaction mixture is transferred to the wells of a streptavidin coated microtitre plate and incubated to capture the complex of biotinylated ubiquitin and GST-cyclin (free biotinylated ubiquitin will also compete for binding sites on the well). The wells are washed with buffer to remove uncomplexed GST-cyclin. Binding of ubiquitinated GST-cyclin is monitored with a detection system, based either on a biochemical assay for GST (e.g., 1-chloro-2,4-dinitrobenzene, Pharmacia catalog no. 27-4590-01) or an immunological assay using goat anti-GST antibody (Pharmacia catalog no. 27-4590-01).

Example 6

Antibodies and Proteins

Purified monoclonal MPM-2 antibodies (Davis *et al.*, 1983) were prepared by standard techniques. Rabbit antibodies were raised against human UBC4 according to known methods. In immunoblotting experiments antisera used at a dilution of 1:300 recognized a major band of 15 kDa in crude *Xenopus* egg extract and in fraction Q1 that was absent from fraction Q2. The antibodies did not immunoprecipitate native UBC4. Monoclonal antibody 1C5 specific for E1 (Schwartz *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:5542) was prepared according to standard methods. Rabbit antibodies raised against human CDC27 and CDC16 proteins were used for immunoblotting at a dilution of 1:2000. Immunoblots were visualized using the ECL detection system (Amersham).

Bovine ubiquitin was from Sigma. An N-terminal fragment of sea urchin cyclin B, consisting of residues 13-110, and a corresponding fragment containing a mutated destruction box (R42A, A44R) were expressed in *E. coli*, and purified as described (Holloway *et al.* (1993) *Cell* 73:1393). Recombinant human UBC4 and E1 were purified according to standard techniques.

Preparation of Extracts and High-Speed Supernatants

Different types of concentrated extracts were prepared from laid *Xenopus laevis* eggs. Interphase extracts were prepared as described (Murray (1991) *Methods Cell Biol.* 36:581).

except that eggs were activated with the calcium ionophore A23187 (Calbiochem) at a concentration of 1 µg/ml. Cycloheximide was added to arrest the extracts in interphase. To generate mitotic Δ90 extracts, a bacterially-expressed, non-degradable 90 fragment of sea urchin cyclin B was added to interphase extracts at a concentration of 60 µg/ml. This keeps the cyclin degradation system constitutively activated (Glutzer *et al.* (1991) *op. cit.*). A different mitotic extract was prepared from non-activated metaphase II arrested eggs according to the protocol described by Kuang and colleagues for "mature oocyte extracts" (Kuang *et al.* (1991) *Proc. Natl. Acad. Sci. USA* **88**:11530). Okadaic acid (Calbiochem) was added to a concentration of 1 µM which is known to activate the cyclin degradation system in such extracts (Lorca *et al.* (1991) *Mol. Cell. Biol.* **11**:1171).

For the generation of high-speed supernatants, extracts were diluted 10-fold in buffer Q-A (20 mM Tris-HCl, pH 7.7, 100 mM KCl, 0.1 mM CaCl₂, 1 mM MgCl₂, 1 mM dithiothreitol (DTT) containing an energy-regenerating system (7.5 mM creatine phosphate, 1 mM adenosine triphosphate (ATP), 0.1 mM EGTA, 1 mM MgCl₂, pH 7.7) and okadaic acid (1 µM, mitotic extracts only), and were centrifuged for 1 h at 115,000 x g at 4 °C. The supernatant was reconcentrated to 50% of the original extract volume in Centriprep-10 concentrators (Amicon). Pellet and membrane fractions were separately resuspended in the dilution buffer, centrifuged again, and resuspended in 50% of the original volume. Extracts, pellet, membrane and supernatant fractions were stored at -70 °C.

In some cases, the extracts from metaphase II eggs were thiophosphorylated to generate stably phosphorylated proteins, using the protocol described by Kuang *et al.* (1991: *op. cit.*) with modifications (data not shown). Briefly, protein from 500 ml of extract was precipitated with 0-40% ammonium sulfate, redissolved in 25 ml of extraction buffer (EB: 80 mM glycerophosphate, 15 mM MgCl₂, 20 mM EDTA, 3 mM DTT, pH 7.4) containing 1 µM okadaic acid and 1 mM ATP-γ-S (Boehringer) and clarified by centrifugation for 15 min in a SS34 rotor (Sorvall) at 15,000 rpm. The supernatant was applied to a 175 ml G25 column (Pharmacia) pre-equilibrated with EB containing okadaic acid and ATP-γ-S. The column was eluted with 100 ml of EB. Fractions containing protein or ATP-γ-S were pooled and incubated for 16 h at 4°C and for an additional 2 h at room temperature. The resulting thiophosphorylated fraction was applied to a 50 ml Q Sepharose fast-flow column (Pharmacia). Bound proteins were eluted in two steps with EB containing 200 mM NaCl (QE-I) and with EB containing 400 mM NaCl (QE-II), respectively. Fractions were pooled into flow through, QE-I and QE-II, proteins were precipitated with 40% ammonium sulfate and the resulting pellets were stored at -70 °C.

All fractionation was carried out at 4 °C. Unless otherwise specified, interphase extracts and the corresponding mitotic Δ90 extracts were used as the starting material for all experiments. For generation of fractions Q1 and Q2, 20-40 ml of diluted S100 was applied to

a 6 ml Resource Q column on an FPLC system (Pharmacia) equilibrated with buffer Q-A. Flow-through fractions were combined (Q1), the column washed with 5 column volumes, and bound proteins eluted with 0.5 M KCl in Q-A. Eluted fractions were combined (Q2), desalted on PD10 columns (Pharmacia), and Q1 and Q2 reconcentrated to 50% of the original extract volume.

To generate fractions Q1A and Q1 B, Fraction Q1 derived from 50 ml of diluted S100 was precipitated with 80% ammonium sulfate, redissolved in buffer S-A (10 mM PIPES-KOH, pH 6.5, 30 mM KCl, 1 mM DTT) and gel filtered into the same buffer. The fraction was applied to a 6 ml Resource S column on an FPLC system equilibrated with buffer S-A. After collection of the flow-through fraction (Q1 A), the column was washed with 2 column volumes of buffer S-A, and bound proteins eluted with 0.5 M KCl in S-A (Q1B). Q1A and Q1B were gel filtered into buffer Q-A and reconcentrated as described for fractions Q1 and Q2. Because fraction Q1 B prepared this way contained a small amount of the 30 kDa activity, we raised the KCl concentration in buffer S-A during the Resource S chromatography step to 50 mM, and simplified the purification procedure by applying S100 directly to the Resource S column. This protocol generated a Q1 B fraction that was not contaminated with the activity found in Q1A.

For analysis of Q1A and Q1 B by gel filtration, 1-2 ml samples of concentrated Q1A or Q1B were separated on a Superdex 75 column (1.6 x 60 cm) equilibrated with buffer Q-A on an FPLC system (Pharmacia) at a flow rate of 0.75 ml/min. 5 ml fractions were collected and concentrated 10- to 25-fold. In some cases, ubiquitin or bovine serum albumin (BSA) was added to the fractions to a final concentration of 0.2 mg/ml before reconcentration.

For further fractionation of proteins in Q2, 40 ml of mitotic S100 was applied to the 6 ml Resource Q column. Bound proteins were eluted with six column volumes of a linear salt gradient (0-500 mM KCl in buffer Q-A). 2.5 ml fractions were collected, desalted on PD10 columns and reconcentrated to 0.5 ml. Similar amounts of S100 fractions prepared from metaphase II extracts were fractionated using the same protocol. Thiophosphorylated QE2 fractions (100 mg protein) were also separated this way.

For the determination of sedimentation coefficients, 0.5 ml of a fraction containing MDC obtained by separation of QE-II on Resource Q was further analyzed by sucrose gradient centrifugation. 15-40 % sucrose gradients were centrifuged for 13.5 h at 37,500 rpm in a SW40 rotor (Beckman). 0.85 ml fractions were collected using an Isco gradient fractionator, diluted 1 :4 with buffer Q-A and concentrated to approximately 150 µl each. The positions of the 15S p97-ATPase (Peters *et al.* (1990) *EMBO J.* 9:1757) and of a 10S complex of elongation factors (Belle *et al.* (1989) *FEBS Lett.* 255:101); and data not shown) separated in the same sucrose gradient were used to estimate the S-value of MDC.

For the determination of the apparent molecular weight of MDC, 0.2 ml of a reconcentrated Q column fraction was applied to a 24 ml Superose 6 column (Pharmacia). Fractions of 1 ml were collected at a flow rate of 0.5 ml/min and reconcentrated to 0.1 ml and assayed against interphase S100. The apparent molecular weight was estimated by comparison to the elution profile of a standard mixture of thyroglobulin, ferritin, and bovine serum albumin (Pharmacia).

N-terminal fragments of sea urchin cyclin B (residues 13-110) containing either a wild type or mutated (R42A, A44R) destruction box were labeled to a specific activity of ~100 μ Ci/ μ g protein using the chloramine T procedure (Parker, (1990) *Methods. Enzymol.* 182:721).

Ubiquitination assays were performed in a total volume of 5 or 10 μ l and contained energy-regenerating system, 1.25 mg/ml ubiquitin and 12.5 ng (100 nM) labeled substrate. Reactions were incubated at room temperature for 10-15 min and quenched by addition of sodium-dodecyl-sulfate (SDS)-sample buffer, and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Dried gels were then analyzed by autoradiography or by phosphor imaging using a Molecular Dynamics phosphorimager.

For assay of column fractions against interphase S100, reactions contained 3 μ l of column fraction, 1.25 μ l of interphase S100, ubiquitin, and energy-regenerating system in a total volume of 5 μ l. For assay against E1 and UBC4, reactions contained 3 μ l column fraction, 130 μ g/ml recombinant human E1, 25 μ l/ml recombinant human UBC4, ubiquitin and energy-regenerating system in a final volume of 5 μ l.

For E1-ubiquitin thioester assays, column fractions were incubated with 0.3 μ g iodinated ubiquitin (10 μ Ci/ μ g) in a total volume of 10 μ l in the presence of 5 mM Tris-HCl (pH 7.7), 10 mM $MgCl_2$, 1 mM ATP, 0.1 mM DTT, and 1 U inorganic pyrophosphatase (Sigma). After 5 min at room temperature, reactions were stopped by addition of 10 μ l urea sample buffer (120 mM Tris-HCl, pH 6.8, 4% SDS, 4 M urea, 20% glycerol), and reaction products analyzed by non-reducing SDS-PAGE and autoradiography. For the detection of E2-ubiquitin thioesters, assays were performed as described, except that reaction mixtures contained either 1 μ g recombinant wheat E1 (Hatfield *et al.* (1990) *J. Biol. Chem.* 265:16376), partially purified *Xenopus* E1, or purified recombinant human E1.

MPM-2 monoclonal antibody was purified from mouse hybridoma ascites as described (Kuang *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:4982). 0.25 volumes of purified MPM-2 antibody (1 Omg/ml) or control antibody (purified total mouse IgG (Sigma). 10 mg/ml) was added to fraction Q1 or Q2 (final volume 13.5 μ l) and the mixture incubated for 20 minutes on ice. Protein A-Sepharose beads (5 μ l: Sigma) were then added, and the incubation continued on ice for 40 minutes with frequent mixing. Beads were removed by centrifugation, and the supernatant tested for ubiquitination activity.

For CDC27 immunodepletion and reconstitution experiments, one volume of crude anti-CDC27 rabbit serum or preimmune serum was incubated with two volumes of protein A-sepharose beads (Biorad) for 2 hours at 4°C. Beads were washed 5 times in buffer Q-A, and then incubated in five volumes of the appropriate fraction for 2 hours at 4°C. Beads were washed 5 times in Q-A buffer containing 500 mM KCl, and three times in buffer Q-A. For immunoblot analysis, 10 µl of washed beads were eluted with 100 µl SDS-sample buffer and boiled; 20 µl was analyzed by SDS-PAGE and subsequent immunoblotting. For ubiquitination assays, 5 µl of washed beads was incubated with 6 µl of a mix containing either interphase S100, or with a mixture of recombinant E1 (260 µg/ml) and UBC4 (50 µg/ml); both mixes contained energy-regenerating system, ubiquitin, and labeled substrate at the concentrations indicated above.

As a substrate for the ubiquitin conjugation reaction, we used an iodinated N-terminal fragment of sea urchin cyclin B, consisting of residues 13-110. We monitored the formation of radiolabeled cyclin-ubiquitin conjugates by SDS-PAGE and autoradiography. The ubiquitination and degradation of this protein is dependent upon the cell-cycle state of crude extracts and requires an intact destruction box (Holloway *et al.* (1993) *Cell* 73:1393 ; and data not shown). As a source of factors required for cyclin ubiquitination, we prepared concentrated interphase extracts from *Xenopus* eggs activated with calcium ionophore in the presence of cycloheximide. Stable mitotic extracts that constitutively degrade cyclin B were then obtained by addition of the non-degradable Δ90 fragment of sea urchin cyclin B (Glotzer *et al.* (1991) *op cit.*).

Our protocol for the separation of mitotic *Xenopus* extracts into fractions required for cyclin ubiquitination activity is shown in Figure 1. As a first step, we prepared pellet, membrane, and supernatant (S100) fractions by high-speed centrifugation of diluted, crude mitotic extracts. Okadaic acid was added to prevent reversal of the mitotic state. Cyclin ubiquitination activity was recovered in the S100 fraction after reconcentration to the original volume, as indicated by the ladder-like appearance of higher-molecular-weight species upon SDS-PAGE analysis. Ubiquitin conjugates were observed within one to two minutes of incubation in the mitotic supernatant, and reached a steady state within five minutes (data not shown). The substrate was also degraded in this fraction with a half-life of approximately five minutes, similar to that observed in crude extracts (data not shown). No ubiquitination activity was detectable in the washed pellet or membrane fractions by SDS-PAGE analysis.

We fractionated mitotic S100 by anion exchange chromatography, using Resource Q as a resin, yielding a flow through fraction (Q1) and a 0.6 M KCl eluate (Q2). While neither fraction alone catalyzed cyclin ubiquitination, mixing the fractions fully reconstituted activity (Fig. 1C). A destruction box mutant (R42A, A44R) produced only low-molecular-weight conjugates. To determine whether both of these fractions were mitotically regulated, we

prepared Q1 and Q2 from interphase S100 (designated Q1ⁱ and Q2ⁱ). Cyclin ubiquitination was observed when Q1 was replaced by Q1ⁱ but not when Q2 was replaced by Q2ⁱ, indicating that only Q2 is mitotically regulated.

We had observed that addition of the monoclonal antibody MPM-2, which recognizes a subset of proteins phosphorylated in mitosis, could inhibit cyclin ubiquitination and degradation when added to crude mitotic extracts (data not shown). We found that immunodepletion of fraction Q2 with the MPM-2 antibody strongly inhibited cyclin ubiquitination, while depletion of fraction Q1 had no effect. Control depletions using total mouse IgG or an unrelated monoclonal antibody were not inhibitory. This result further suggests that Q2 is subject to mitotic regulation.

To identify components in the unregulated fraction required for cyclin ubiquitination, we further fractionated Q1 by gel filtration and tested each fraction for its ability to complement Q2. We found complementing activity in a broad molecular weight range corresponding to 15-40 kDa, suggesting that multiple components in Q1 might each be sufficient to complement Q2 (data not shown). To test this idea, we fractionated Q1 by Resource S chromatography, and generated a flow-through fraction (Q1A) and a 0.6 M KCl eluate (Q1B). Each fraction was sufficient to complement Q2, and was therefore further fractionated by gel filtration. The peak of activity in fraction Q1A eluted at 70 ml, corresponding to a molecular weight of ~30 kDa; activity in fraction Q1B peaked at 81 ml, corresponding to ~20 kDa. The pattern of ubiquitin conjugates generated by Q1A and Q1B was somewhat different: Q1A favored the production of low-molecular-weight conjugates, whereas Q1B generated higher-molecular-weight conjugates, suggesting that these activities are distinct. Ubiquitination mediated by both Q1A and Q1B required an intact cyclin destruction box (data not shown).

As ubiquitin-conjugating enzymes typically range in size from 14 to 28 kDa, we tested gel filtration fractions derived from Q1A and Q1B for the presence of E2s by determining whether specific thioesters were formed in the presence of radiolabeled ubiquitin and purified E1. Fraction Q1A contained multiple ubiquitin thioesters of 24 - 34 kDa that copurified with cyclin-conjugating activity. By contrast, the activity in fraction Q1B copurified with a single predominant thioester of 22 kDa, suggesting the presence of a 15-16 kDa E2. As this thioester did not cofractionate with the peak of activity in fraction Q1A, there appear to be at least two different E2s in fraction Q1 sufficient to complement Q2.

Only very few E2s characterized to date would be expected to behave chromatographically like the activity in fraction Q1B to bind cation exchange resins. One of these, a *Xenopus* homolog of UBC9, did not cofractionate with activity (data not shown). Another is represented by the UBC4/5 class of proteins, homologs of which have been demonstrated to bind cation exchange resins (Girod and Vierstra (1993) *J. Biol. Chem.*

268:955; Scheffner *et al.* (1993) *Cell* 75:495). Fraction Q1B showed strong UBC4 immunoreactivity that cofractionated with cyclin ubiquitination activity during gel filtration, while fraction Q1A contained only a small amount of UBC4 that did not copurify with the majority of activity. Therefore, we tested whether bacterially-expressed and purified human UBC4 was sufficient to complement fraction Q2. UBC4 supported cyclin ubiquitination in a dose-dependent fashion (Figure 2). Strong complementation was observed at 6 μ g/ml, the lowest concentration tested, and became maximal at 25 μ g/ml. Quantitative immunoblotting demonstrated that UBC4 is present in fraction Q1 at a concentration of approximately 4 μ g/ml (data not shown). In contrast, other purified E2s such as human CDC34 had no effect, even at high dose; human UBC2 only weakly supported cyclin ubiquitination (Figure 2). This difference was not due to a difference in ability to accept ubiquitin from E1, because UBC2, UBC4 and CDC34 formed similar amounts of ubiquitin thioesters (data not shown). A destruction box mutant yielded only low molecular weight conjugates in the presence of recombinant UBC4, suggesting that substrate specificity is maintained in this reconstituted system.

Immunoblotting demonstrated the presence of E1 in fraction Q2 only (data not shown); its activity did not appear cell-cycle regulated as both Q2 and Q2ⁱ supported formation of a prominent ~120 kDa E1-ubiquitin thioester. Neither purified *Xenopus* E1 nor recombinant E1 was able to complement fraction Q2, suggesting that Q2 contained additional components required for cyclin ubiquitination. To identify mitotically-regulated components, mitotic S100 was applied to the Resource Q column and eluted with a linear 100-600 mM KCl gradient. Fractions were gel filtered, reconcentrated, and tested for their ability to complement interphase S100, which should contain all of the non-mitotically-regulated components. Interphase S100-complementing activity eluted as a major peak at 400 mM KCl (Fraction 11). E1, as measured by thioester formation with radiolabeled ubiquitin, eluted at approximately 200 mM KCl (Fractions 4 and 5). As expected, the E1-containing fractions did not strongly complement interphase S100. The peak fraction retained destruction-box dependence when assayed against interphase S100. Significantly, the peak fraction was sufficient to complement a mixture of recombinant E1, UBC4 and ubiquitin, suggesting that this activity did not simply convert the inactive interphase fraction into an active mitotic fraction. Identical results were obtained using mitotic S100 prepared from three different sources: cyclin Δ 90-activated extracts, extracts from metaphase-II-arrested eggs, or egg extracts that had been thiophosphorylated to stabilize mitotic phosphorylation as described above (data not shown). These data suggest that the mitotically-regulated activity contains a mitosis-specific cyclin-ubiquitin ligase, as it can complement either interphase S100 or a mixture of purified E1 and UBC4.

To further characterize the mitotic activity in fraction Q2, we generated a Q eluate fraction from thiophosphorylated mitotic extracts that we refer to as fraction QE2 (see

above). This fraction was reapplied to the Resource Q column, and the peak of activity, eluting at 400 mM KCl, was gel-filtered, reconcentrated, and fractionated by sucrose gradient centrifugation. A peak of interphase S100-complementing activity sedimented as a large discrete complex of approximately 20-22S. Peak fractions could also complement recombinant E1 and UBC4 (data not shown). Fractionation of the 400 mM Q eluate over a Superose 6 column indicated an apparent molecular weight between 1×10^6 and 1.5×10^6 Da (data not shown).

CDC16 and CDC23 have been demonstrated to physically interact with CDC27 in yeast (Lamb *et al.* (1994) *EMBO J.* 13:4321). In human cultured cells, CDC16 and CDC27 are components of an approximately 20S complex (data not shown). Therefore, we tested the peak sucrose gradient fractions described above for the presence of these proteins. Immunoblot analyses were performed using antibodies generated against human homologs of CDC16 and CDC27. It was found that CDC27 and CDC16 both cofractionated with activity. The corresponding preimmune sera showed no reactivity (data not shown). Further immunoblotting experiments revealed that both proteins also cofractionated with ubiquitination activity during Resource Q and gel filtration chromatography (data not shown). We found that CDC27 derived from QE2 migrated heterogeneously on SDS-PAGE analysis, with a relative molecular weight (M_r) of 115-140 kDa. CDC27 derived from interphase extracts migrated with an M_r of approximately 100 kDa, suggesting that CDC27 is modified in mitosis (see below). CDC16 also appears to be modified in mitosis, as it migrated with an M_r corresponding to 72 kDa in interphase extracts and 74 kDa in mitotic extracts.

To further examine the role of CDC27 and CDC16 in cyclin B ubiquitination, we immunodepleted fraction QE2 with antibodies raised against the human homolog of CDC27, and assayed the supernatant for ability to complement interphase S100. Immunodepletion of fraction QE2 completely inhibited its ability to complement interphase S100, while preimmune sera had no effect. This treatment effectively depleted the majority of CDC27 protein, and also removed a substantial portion of the CDC16 protein, suggesting that, as in yeast and humans, the two proteins form a complex (see below). Antisera raised against human CDC16 were not effective in immunodepleting either CDC16 or CDC27 proteins, nor did they deplete ubiquitin-conjugating activity (data not shown).

We next tested whether stringently-washed CDC27 immunoprecipitates derived from fraction QE2 were sufficient to complement interphase S100. CDC27 antibodies or preimmune antibodies were bound to protein A beads, washed, and incubated with fraction QE2 for 2 hours at 4°C. Beads were subsequently washed 5 times in buffer containing 500 mM KCl, and three times in buffer containing 100 mM KCl. CDC27 antibody beads derived from QE2 were capable of complementing interphase S100. This activity required the

presence of an intact cyclin destruction box for generation of high-molecular weight conjugates.

We also tested the mitotic immunoprecipitate in a defined system composed of recombinant E1, UBC4, and purified ubiquitin. A CDC27 immunoprecipitate complemented these defined components, while the preimmune immunoprecipitate did not. The production of high molecular weight conjugates was reduced when the cyclin destruction box mutant was assayed. However, the discrimination between the wild-type and mutant substrate was not as strong when the CDC27 immunoprecipitate was tested against E1 and UBC4 as it was when tested against interphase S100. The reduced specificity in the defined reaction is unlikely to be related to the use of purified UBC4, because destruction-box dependence of the reaction is fully maintained when UBC4 is used to complement total fraction Q2 (as described *supra*). This may indicate that components required for full destruction-box-dependence may be partially lost during immunoprecipitation.

To determine whether CDC16 is present in a complex with CDC27, we immunoprecipitated CDC27 from either crude extracts or supernatant fractions. After stringent washing, we analyzed the immunoprecipitates for the presence of CDC27 and CDC16 by immunoblotting. We found that CDC27 was immunoprecipitated from crude interphase and mitotic extracts, and from interphase S100 and QE2 fractions. As described earlier, CDC27 derived from crude interphase extracts or S100 migrated with a relative molecular weight (M_r) of 100 kDa on denaturing polyacrylamide gels. However, when derived from a crude mitotic extract, slower migrating forms became apparent. This effect was enhanced by thiophosphorylation, because CDC27 derived from fraction QE2 had a further reduced mobility. Analysis of the immunoprecipitates by immunoblotting with CDC16 antibodies revealed that CDC16 co-immunoprecipitated with CDC27 under all of the conditions tested. The mobility of CDC16 also appeared to be reduced when derived from either crude mitotic extracts or fraction QE2, suggesting that it may also be modified in mitosis. These data suggest that at least a fraction of CDC16 is tightly associated with CDC27 in both interphase and mitosis.

The proteolysis of cyclin is a key event in the cell cycle that irreversibly signals exit from mitosis. Through the activation of cdc2 kinase, a process is initiated that targets cyclin for destruction by the ubiquitin system (Murray *et al.* (1989) *Nature* 339:280; Felix *et al.*, (1990) *Nature* 346:379). Mitotic cyclins share a small conserved sequence, the destruction box, which is necessary for ubiquitination and subsequent proteolysis (Glotzer *et al.* (1991) *op. cit.*). To determine the basis of the substrate and cell cycle specificity of cyclin ubiquitination, we have fractionated mitotic extracts to identify components required for this process. In addition to the universally-required components, E1 and ubiquitin, we have found three distinct activities that can reconstitute mitotic cyclin ubiquitination. The first two

activities are a set of ubiquitin conjugating enzymes that include UBC4, known to be involved in the conjugation of ubiquitin to many cellular proteins. The third is a novel 20S complex, which we term the Mitotic Destruction Complex (MDC), that contains homologs of two yeast proteins required for anaphase. This complex, which meets the functional criteria
5 for a ubiquitin-protein ligase, is the major determinant of both substrate and cell cycle specificity in the cyclin ubiquitination system.

All ubiquitin conjugation reactions require the participation of at least one of a large family of ubiquitin conjugating enzymes. These enzymes have functional specificity that has been demonstrated both genetically and biochemically (see, e.g., Jentsch (1992) *Ann. Rev. Genet.* 26:179), but it is unclear how such specificity arises. Specific E2 requirements would
10 be expected if E2s recognized and transferred ubiquitin to their substrates directly; however, few E2s appear to have this ability, and the physiological relevance of these reactions remains unclear. Alternatively, E2 functional specificity may arise as a consequence of interaction with a specific E3. This possibility seems especially likely in light of the recent finding that,
15 at least in certain cases, E2s can transfer ubiquitin from E1 to E3 (Scheffner *et al.* (1995) *Nature* 373:81). In this model, both substrate recognition and ubiquitin conjugation would be catalyzed by the E3. Identification of the specific E2s involved in a particular ubiquitination reaction may therefore reveal more about the nature of the E3 involved than about how substrates are recognized.

We find at least two unregulated ubiquitin conjugating enzymes in *Xenopus* extracts that can complement MDC and E1 to ubiquitinate cyclin B. Both of these E2 activities support a destruction-box-dependent reaction, suggesting that they act through a common recognition mechanism. In preliminary experiments, we have not seen any synergy between the two E2 activities. Until we can effectively immunodeplete these proteins from crude
20 extracts and measure degradation, as well as ubiquitination, it will be difficult to assess their relative physiological importance.

Our data strongly suggest that one of the two E2 activities is a *Xenopus* homolog of UBC4. This protein copurifies with activity over ion exchange and gel filtration chromatography, and recombinant human UBC4 can fully complement destruction-box
30 dependent cyclin ubiquitination at concentrations similar to those found in our fractions. The second E2 activity in our fractions remains unidentified. This E2 has a larger apparent molecular weight than UBC4 and may correspond to the recently-described activity in clam eggs called E-2C, for which structural information has not yet been reported (Hershko *et al.* (1994) *J. Biol. Chem.* 269:4940). The *Xenopus* homolog of UBC9, an enzyme implicated in
35 cyclin degradation in yeast (Seufert *et al.* (1995) *Nature* 373:78), does not cofractionate with either of the two activities.

UBC4 has been implicated in the degradation of many different proteins. In yeast, it is required in conjunction with its close homolog UBC5 for the turnover of abnormal proteins (Seufert and Jentsch (1990) *EMBO J.* 2:543), and for the degradation of the transcription factor MAT α 2 (Chen *et al.* (1993) *Cell* 74:357). A UBC4 homolog found in wheat germ extract appears capable of supporting ubiquitin conjugation to many proteins *in vitro* (Girod and Vierstra (1993) *J. Biol. Chem.* 268:955). Mammalian homologs of UBC4 have been shown to participate in the ubiquitination of p53 catalyzed by the E6AP/E6 complex (Scheffner *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:8797). These data suggest that the UBC4/5 family of E2s has the ability to interact with multiple E3s to ubiquitinate a large number of target proteins. The involvement of UBC4 in such varied ubiquitination reactions makes it an unlikely determinant of substrate specificity in the cyclin ubiquitination system.

Mutation of UBC4 family members (UBC4, 5) in yeast has not been reported to cause a clearly-defined cell cycle arrest (Seufert and Jentsch (1990) *op. cit.*). This could be due to either the pleiotropy of the mutation or to a redundancy in E2 function required for cyclin ubiquitination.

Without wishing to be bound by any particular theory, these data suggest that the cell cycle specificity of cyclin ubiquitination is mediated by the Mitotic Destruction Complex, which contains homologs of the yeast proteins CDC27 and CDC16, both of which are required for anaphase. When tested against the inactive S100 fraction from interphase cells, partially purified MDC will reconstitute cyclin ubiquitination to levels found in mitotic extracts. Reconstitution experiments with purified components indicate that MDC plays a direct role in the ubiquitination reaction, and does not simply serve as a regulator of ubiquitination in interphase extracts.

The CDC16 and CDC23 proteins form a complex with the CDC27 protein (Lamb *et al.* (1994), *op. cit.*). Each of these proteins contains several TPR motifs which may mediate protein interactions in this complex. These three genes are required for the onset of anaphase in yeast, and also in mammals, as injection of antibodies specific for human CDC27 result in metaphase arrest (data not shown). Using antibodies generated against the human homologs of CDC27 and CDC16, we have shown that they are present in MDC. CDC27 antibodies immunodeplete the mitotically-regulated ubiquitin-protein ligase activity from mitotic fractions, and immunopurified CDC27 complexes can reconstitute cyclin ubiquitination in a defined system composed of recombinant E1 and UBC4, purified ubiquitin, and ATP.

Formally MDC functions as a ubiquitin protein ligase as it is required for the transfer of ubiquitin from an E2, such as UBC4, to the substrate. Two distinct types of ligases have been cloned. Yeast UBR1 mediates N-end rule degradation (Varshavsky (1992) *Cell* 69:724); mammalian E6AP participates in p53 ubiquitination (Huibregtse *et al.* (1991) *EMBO J.* 10:4129; Huibregtse *et al.* (1993) *Mol. Cell Biol.* 13:775; Scheffner *et al.* (1993) *Cell* 75:495)

and shares C-terminal homology with a family of other proteins (Scheffner *et al.*, 1995 *op. cit.*), which may also function as E3s. UBR1 and E6AP do not share homology with each other or with CDC27, CDC16, or CDC23. Recently it has been demonstrated that E6AP can accept ubiquitin from UBC4, forming a thioester at a conserved cysteine residue essential for
5 ligase activity (Scheffner *et al.*, 1995 *op. cit.*). We have not yet been able to observe the formation of a similar thioester with MDC, but we have found that MDC activity is sensitive to the sulfhydryl-reactive reagent N-ethyl maleimide (data not shown).

The activation of cyclin B-cdc2 kinase is required for the activation of cyclin degradation (Murray *et al.*, (1989) *op. cit.*; Luca *et al.* (1991) *EMBO J.* 10:4311). Purified
10 cdc2 kinase triggers cyclin degradation in interphase extracts (Felix *et al.*, 1990), however there is a 15-minute lag period preceding activation, suggesting that the activation of MDC by cdc2 kinase may not be direct. Furthermore, the MPM-2 monoclonal antibody, which recognizes a discrete set of mitotic phosphoproteins, can deplete MDC activity from crude fractions (see above), and can immunoprecipitate CDC27 and CDC16 (data not shown).
15 Phosphorylation of this epitope appears to be mediated, at least in part, by kinases distinct from cdc2 (Kuang and Ashorn (1993) *J. Cell Biol.* 123:859). Therefore, these kinases provide interesting candidates for regulators that function downstream of cdc2 kinase to contribute to the activation of MDC in mitosis. Interestingly, we observed a dramatic upward mobility shift for mitotic CDC27, as compared to the interphase form, and a small shift for
20 CDC16. Preliminary experiments indicate that treatment of CDC27 immunoprecipitates with phosphatase can completely reverse this mobility shift (data not shown), suggesting that altered mobility is a consequence of mitotic phosphophorylation. Such large shifts have been seen for other MPM-2 epitopes, such as cdc25 (Kumagai and Dunphy (1992) *Cell* 70:139; Kuang *et al.* (1994) *Mol. Biol. Cell* 5:135). During the course of mitotic activation, the
25 CDC27 upshift precedes the activation of cyclin ubiquitination, suggesting either a requirement for a threshold level of modification or the existence of additional controls.

Our immunoprecipitation results indicate that CDC27 and CDC16 are associated in both mitosis and interphase. It is therefore possible that an assembled but inactive form of MDC is present in interphase. We are currently characterizing the interphase form of MDC to
30 determine how it becomes activated in mitosis.

Biochemical and genetic evidence have now converged to suggest that cyclin degradation and sister chromatin segregation are mediated by a common set of components including CDC16, CDC23, and CDC27. This complex may have functions in addition to cyclin ubiquitination, as certain mutant alleles of CDC16 and CDC27 block anaphase
35 progression but do not interfere with cyclin degradation. One such function of this complex might be the ubiquitination of substrates other than mitotic cyclins whose degradation is required for the onset of anaphase. The existence of such proteins is suggested by the finding

that an N-terminal fragment of cyclin B can inhibit the onset of anaphase in extracts that contain no other cyclin than exogenously added non-degradable cyclin (Holloway *et al.* (1993) *op. cit.*). Furthermore, methylated ubiquitin interferes with sister chromatin separation, suggesting the involvement of ubiquitin-mediated proteolysis in this process.

5 MDC may therefore ubiquitinate several proteins whose degradation is required for anaphase, explaining why some but not all CDC16 alleles interfere with cyclin degradation in yeast. Alternatively, it is of course also possible that MDC has functions which are independent of its ubiquitin protein ligase activity.

10 Why the cyclin-ubiquitin ligase is contained in such a large complex is presently a mystery. Some insight into this problem may be found in the observation in fungi and mammalian cells that CDC27 and CDC16 localize to the mitotic spindle and centrosomes (Mirabito and Morris (1993) *J. Cell Biol.* 120:959), structures that have also been found to be associated with MPM-2 antigens and cyclin B (Engle *et al.* (1988) *Cell Motil. Cytoskeleton* 10:434; Bailly *et al.* (1992) *J. Cell Sci.* 101:529; Debec and Montmory (1992) *Biol. Cell* 75:121; Maldonado and Glover (1992) *J. Cell Biol.* 116:967; Vandre *et al.* (1986) *Eur. J. Cell Biol.* 41:72). The association of MDC with these structures may be important for its regulation, transmitting information regarding the state of spindle assembly to the mitotic degradation machinery. Additional levels of control may be imposed by activities such as
15 cytostatic factor that arrest cell division at metaphase II of meiosis. MDC may therefore
20 serve as a common target of controls that regulate the onset of anaphase.

All of the above-cited references and publications are hereby incorporated by reference.

Equivalents

25 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific assay and reagents described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.

-40-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: President and Fellows of Harvard College
(B) STREET: 124 Mt. Auburn Street
(C) CITY: Cambridge
(D) STATE: MA
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 02138

(ii) TITLE OF INVENTION: Assay and Reagents for Detecting Inhibitors of
Degradation of Cell Cycle Regulatory Proteins

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (text)

(v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/425,299
(B) FILING DATE: 20-APR-1995

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Vincent, Matthew P.
(B) REGISTRATION NUMBER: 36,709
(C) REFERENCE/DOCKET NUMBER: HMI-014

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 227-7400
(B) TELEFAX: (617) 227-5941

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1302 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..1299

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

-41-

	ATG GCG CTC CGA GTC ACC AGG AAC TCG AAA ATT AAT GCT GAA AAT AAG	48
	Met Ala Leu Arg Val Thr Arg Asn Ser Lys Ile Asn Ala Glu Asn Lys	
	1 5 10 15	
5	GCG AAG ATC AAC ATG GCA GGC GCA AAG CGC GTT CCT ACG GCC CCT GCT	96
	Ala Lys Ile Asn Met Ala Gly Ala Lys Arg Val Pro Thr Ala Pro Ala	
	20 25 30	
10	GCA ACC TCC AAG CCC GGA CTG AGG CCA AGA ACA GCT CTT GGG GAC ATT	144
	Ala Thr Ser Lys Pro Gly Leu Arg Pro Arg Thr Ala Leu Gly Asp Ile	
	35 40 45	
15	GGT AAC AAA GTC AGT GAA CAA CTG CAG GCC AAA ATG CCT ATG AAG AAG	192
	Gly Asn Lys Val Ser Glu Gln Leu Gln Ala Lys Met Pro Met Lys Lys	
	50 55 60	
20	GAA GCA AAA CCT TCA GCT ACT GGA AAA GTC ATT GAT AAA AAA CTA CCA	240
	Glu Ala Lys Pro Ser Ala Thr Gly Lys Val Ile Asp Lys Lys Leu Pro	
	65 70 75 80	
25	AAA CCT CTT GAA AAG GTA CCT ATG CTG GTG CCA GTG CCA GTG TCT GAG	288
	Lys Pro Leu Glu Lys Val Pro Met Leu Val Pro Val Pro Val Ser Glu	
	85 90 95	
30	CCA GTG CCA GAG CCA GAA CCT GAG CCA GAA CCT GAG CCT GTT AAA GAA	336
	Pro Val Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Val Lys Glu	
	100 105 110	
35	GAA AAA CTT TCG CCT GAG CCT ATT TTG GTT GAT ACT GCC TCT CCA AGC	384
	Glu Lys Leu Ser Pro Glu Pro Ile Leu Val Asp Thr Ala Ser Pro Ser	
	115 120 125	
40	CCA ATG GAA ACA TCT GGA TGT GCC CCT GCA GAA GAA GAC CTG TGT CAG	432
	Pro Met Glu Thr Ser Gly Cys Ala Pro Ala Glu Glu Asp Leu Cys Gln	
	130 135 140	
45	GCT TTC TCT GAT GTA ATT CTT GCA GTA AAT GAT GTG GAT GCA GAA GAT	480
	Ala Phe Ser Asp Val Ile Leu Ala Val Asn Asp Val Asp Ala Glu Asp	
	145 150 155 160	
50	GGA GCT GAT CCA AAC CTT TGT AGT GAA TAT GTG AAA GAT ATT TAT GCT	528
	Gly Ala Asp Pro Asn Leu Cys Ser Glu Tyr Val Lys Asp Ile Tyr Ala	
	165 170 175	
55	TAT CTG AGA CAA CTT GAG GAA GAG CAA GCA GTC AGA CCA AAA TAC CTA	576
	Tyr Leu Arg Gln Leu Glu Glu Glu Gln Ala Val Arg Pro Lys Tyr Leu	
	180 185 190	
60	CTG GGT CGG GAA GTC ACT GGA AAC ATG AGA GCC ATC CTA ATT GAC TGG	624
	Leu Gly Arg Glu Val Thr Gly Asn Met Arg Ala Ile Leu Ile Asp Trp	
	195 200 205	
65	CTA GTA CAG GTT CAA ATG AAA TTC AGG TTG TTG CAG GAG ACC ATG TAC	672
	Leu Val Gln Val Gln Met Lys Phe Arg Leu Leu Gln Glu Thr Met Tyr	
	210 215 220	
70	ATG ACT GTC TCC ATT ATT GAT CGG TTC ATG CAG AAT AAT TGT GTG CCC	720
	Met Thr Val Ser Ile Ile Asp Arg Phe Met Gln Asn Asn Cys Val Pro	

-42-

	225	230	235	240	
5	AAG AAG ATG CTG CAG CTG GTT GGT GTC ACT GCC ATG TTT ATT GCA AGC Lys Lys Met Leu Gln Leu Val Gly Val Thr Ala Met Phe Ile Ala Ser	245	250	255	768
10	AAA TAT GAA GAA ATG TAC CCT CCA GAA ATT GGT GAC TTT GCT TTT GTG Lys Tyr Glu Glu Met Tyr Pro Pro Glu Ile Gly Asp Phe Ala Phe Val	260	265	270	816
15	ACT GAC AAC ACT TAT ACT AAG CAC CAA ATC AGA CAG ATG GAA ATG AAG Thr Asp Asn Thr Tyr Thr Lys His Gln Ile Arg Gln Met Glu Met Lys	275	280	285	864
20	ATT CTA AGA GCT TTA AAC TTT GGT CTG GGT CGG CCT CTA CCT TTG CAC Ile Leu Arg Ala Leu Asn Phe Gly Leu Gly Arg Pro Leu Pro Leu His	290	295	300	912
25	TTC CTT CGG AGA GCA TCT AAG ATT GGA GAG GTT GAT GTC GAG CAA CAT Phe Leu Arg Arg Ala Ser Lys Ile Gly Glu Val Asp Val Glu Gln His	305	310	315	960
30	ACT TTG GCC AAA TAC CTG ATG GAA CTA ACT ATC TTG GAC TAT GAC ATG Thr Leu Ala Lys Tyr Leu Met Glu Leu Thr Ile Leu Asp Tyr Asp Met	325	330	335	1008
35	GTG CAC TTT CCT CCT TCT CAA ATT GCA GCA GGA GCT TTT TGC TTA GCA Val His Phe Pro Pro Ser Gln Ile Ala Ala Gly Ala Phe Cys Leu Ala	340	345	350	1056
40	CTG AAA ATT CTG GAT AAT GGT GAA TGG ACA CCA ACT CTA CAA CAT TAC Leu Lys Ile Leu Asp Asn Gly Glu Trp Thr Pro Thr Leu Gln His Tyr	355	360	365	1104
45	CTG TCA TAT ACT GAA GAA TCT CTT CTT CCA GTT ATG CAG CAC CTG GCT Leu Ser Tyr Thr Glu Glu Ser Leu Leu Pro Val Met Gln His Leu Ala	370	375	380	1152
50	AAG AAT GTA GTC ATG GTA AAT CAA GGA CTT ACA AAG CAC ATG ACT GTC Lys Asn Val Val Met Val Asn Gln Gly Leu Thr Lys His Met Thr Val	385	390	395	1200
55	AAG AAC AAG TAT GCC ACA TCG AAG CAT GCT AAG ATC AGC ACT CTA CCA Lys Asn Lys Tyr Ala Thr Ser Lys His Ala Lys Ile Ser Thr Leu Pro	405	410	415	1248
60	CAG CTG AAT TCT GCA CTA GTT CAA GAT TTA GCC AAG GCT GTG GCA AAG Gln Leu Asn Ser Ala Leu Val Gln Asp Leu Ala Lys Ala Val Ala Lys	420	425	430	1296
65	GTG TAA Val				1302

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

-43-

(A) LENGTH: 2472 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

10

(A) NAME/KEY: CDS

(B) LOCATION: 1..2469

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15	ATG ACG GTG CTG CAG GAA CCC GTC CAG GCT GCT ATA TGG CAA GCA CTA	48
	Met Thr Val Leu Gln Glu Pro Val Gln Ala Ala Ile Trp Gln Ala Leu	
	1 5 10 15	
20	AAC CAC TAT GCT TAC CGA GAT GCG GTT TTC CTC GCA GAA CGC CTT TAT	96
	Asn His Tyr Ala Tyr Arg Asp Ala Val Phe Leu Ala Glu Arg Leu Tyr	
	20 25 30	
25	GCA GAA GTA CAC TCA GAA GAA GCC TTG TTT TTA CTG GCA ACC TGT TAT	144
	Ala Glu Val His Ser Glu Glu Ala Leu Phe Leu Leu Ala Thr Cys Tyr	
	35 40 45	
30	TAC CGC TCA GGA AAG GCA TAT AAA GCA TAT AGA CTC TTG AAA GGA CAC	192
	Tyr Arg Ser Gly Lys Ala Tyr Lys Ala Tyr Arg Leu Leu Lys Gly His	
	50 55 60	
35	AGT TGT ACT ACA CCG CAA TGC AAA TAC CTG CTT GCA AAA TGT TGT GTT	240
	Ser Cys Thr Thr Pro Gln Cys Lys Tyr Leu Leu Ala Lys Cys Cys Val	
	65 70 75 80	
40	GAT CTC AGC AAG CTT GCA GAA GGG GAA CAA ATC TTA TCT GGT GGA GTG	288
	Asp Leu Ser Lys Leu Ala Glu Gly Glu Gln Ile Leu Ser Gly Gly Val	
	85 90 95	
45	TTT AAT AAG CAG AAA AGC CAT GAT GAT ATT GTT ACT GAG TTT GGT GAT	336
	Phe Asn Lys Gln Lys Ser His Asp Asp Ile Val Thr Glu Phe Gly Asp	
	100 105 110	
50	TCA GCT TGC TTT ACT CTT TCA TTG TTG GGA CAT GTA TAT TGC AAG ACA	384
	Ser Ala Cys Phe Thr Leu Ser Leu Leu Gly His Val Tyr Cys Lys Thr	
	115 120 125	
55	GAT CGG CTT GCC AAA GGA TCA GAA TGT TAC CAA AAG AGC CTT AGT TTA	432
	Asp Arg Leu Ala Lys Gly Ser Glu Cys Tyr Gln Lys Ser Leu Ser Leu	
	130 135 140	
60	AAT CCT TTC CTC TGG TCT CCC TTT GAA TCA TTA TGT GAA ATA GGT GAA	480
	Asn Pro Phe Leu Trp Ser Pro Phe Glu Ser Leu Cys Glu Ile Gly Glu	
	145 150 155 160	
65	AAG CCA GAT CCT GAC CAA ACA TTT AAA TTC ACA TCT TTA CAG AAC TTT	528
	Lys Pro Asp Pro Asp Gln Thr Phe Lys Phe Thr Ser Leu Gln Asn Phe	
	165 170 175	
	AGC AAC TGT CTG CCC AAC TCT TGC ACA ACA CAA GTA CCT AAT CAT AGT	576

-44-

	Ser	Asn	Cys	Leu	Pro	Asn	Ser	Cys	Thr	Thr	Gln	Val	Pro	Asn	His	Ser	
				180					185					190			
5	TTA	TCT	CAC	AGA	CAG	CCT	GAG	ACA	GTT	CTT	ACG	GAA	ACA	CCC	CAG	GAC	624
	Leu	Ser	His	Arg	Gln	Pro	Glu	Thr	Val	Leu	Thr	Glu	Thr	Pro	Gln	Asp	
				195				200					205				
10	ACA	ATT	GAA	TTA	AAC	AGA	TTG	AAT	TTA	GAA	TCT	TCC	AAT	TCA	AAG	TAC	672
	Thr	Ile	Glu	Leu	Asn	Arg	Leu	Asn	Leu	Glu	Ser	Ser	Asn	Ser	Lys	Tyr	
				210				215					220				
15	TCC	TTG	AAT	ACA	GAT	TCC	TCA	GTG	TCT	TAT	ATT	GAT	TCA	GCT	GTA	ATT	720
	Ser	Leu	Asn	Thr	Asp	Ser	Ser	Val	Ser	Tyr	Ile	Asp	Ser	Ala	Val	Ile	
						230					235				240		
20	TCA	CCT	GAT	ACT	GTC	CCA	CTG	GGA	ACA	GGA	ACT	TCC	ATA	TTA	TCT	AAA	768
	Ser	Pro	Asp	Thr	Val	Pro	Leu	Gly	Thr	Gly	Thr	Ser	Ile	Leu	Ser	Lys	
					245					250					255		
25	CAG	GTT	CAA	AAT	AAA	CCA	AAA	ACT	GGT	CGA	AGT	TTA	TTA	GGA	GGA	CCA	816
	Gln	Val	Gln	Asn	Lys	Pro	Lys	Thr	Gly	Arg	Ser	Leu	Leu	Gly	Gly	Pro	
					260					265				270			
30	GCA	GCT	CTT	AGT	CCA	TTA	ACC	CCA	AGT	TTT	GGG	ATT	TTG	CCA	TTA	GAA	864
	Ala	Ala	Leu	Ser	Pro	Leu	Thr	Pro	Ser	Phe	Gly	Ile	Leu	Pro	Leu	Glu	
				275					280					285			
35	ACC	CCA	AGT	CCT	GGA	GAT	GGA	TCC	TAT	TTA	CAA	AAC	TAC	ACT	AAT	ACA	912
	Thr	Pro	Ser	Pro	Gly	Asp	Gly	Ser	Tyr	Leu	Gln	Asn	Tyr	Thr	Asn	Thr	
				290				295					300				
40	CCT	CCT	GTA	ATT	GAT	GTG	CCA	TCC	ACC	GGA	GCC	CCT	TCA	AAA	AAG	TCT	960
	Pro	Pro	Val	Ile	Asp	Val	Pro	Ser	Thr	Gly	Ala	Pro	Ser	Lys	Lys	Ser	
				305			310				315					320	
45	GTT	GCC	AGA	ATC	GGC	CAA	ACT	GGA	ACA	AAG	TCT	GTC	TTC	TCA	CAG	AGT	1008
	Val	Ala	Arg	Ile	Gly	Gln	Thr	Gly	Thr	Lys	Ser	Val	Phe	Ser	Gln	Ser	
					325					330					335		
50	GGA	AAT	AGC	CGA	GAG	GTA	ACT	CCA	ATT	CTT	GCA	CAA	ACA	CAA	AGT	TCT	1056
	Gly	Asn	Ser	Arg	Glu	Val	Thr	Pro	Ile	Leu	Ala	Gln	Thr	Gln	Ser	Ser	
					340				345					350			
55	GGT	CCA	CAA	ACA	AGT	ACA	ACA	CCT	CAG	GTA	TTG	AGC	CCC	ACT	ATT	ACA	1104
	Gly	Pro	Gln	Thr	Ser	Thr	Thr	Pro	Gln	Val	Leu	Ser	Pro	Thr	Ile	Thr	
					355				360					365			
60	TCT	CCC	CCA	AAC	GCA	CTA	CCT	CGA	AGA	AGT	TCA	CGA	CTC	TTT	ACT	AGT	1152
	Ser	Pro	Pro	Asn	Ala	Leu	Pro	Arg	Arg	Ser	Ser	Arg	Leu	Phe	Thr	Ser	
					370			375					380				
65	GAC	AGC	TCC	ACA	ACC	AAG	GAG	AAT	AGC	AAA	AAA	TTA	AAA	ATG	AAG	TTT	1200
	Asp	Ser	Ser	Thr	Thr	Lys	Glu	Asn	Ser	Lys	Lys	Leu	Lys	Met	Lys	Phe	
						390					395				400		
70	CCA	CCT	AAA	ATC	CCA	AAC	AGA	AAA	ACA	AAA	AGT	AAA	ACT	AAT	AAA	GGA	1248
	Pro	Pro	Lys	Ile	Pro	Asn	Arg	Lys	Thr	Lys	Ser	Lys	Thr	Asn	Lys	Gly	
						405					410				415		

	GGA ATA ACT CAA CCT AAC ATA AAT GAT AGC CTG GAA ATT ACA AAA TTG	1296
	Gly Ile Thr Gln Pro Asn Ile Asn Asp Ser Leu Glu Ile Thr Lys Leu	
	420 425 430	
5	GAC TCT TCC ATC ATT TCA GAA GGG AAA ATA TCC ACA ATC ACA CCT CAG	1344
	Asp Ser Ser Ile Ile Ser Glu Gly Lys Ile Ser Thr Ile Thr Pro Gln	
	435 440 445	
10	ATT CAG GCC TTT AAT CTA CAA AAA GCA GCA GCA GGT TTG ATG AGC CTT	1392
	Ile Gln Ala Phe Asn Leu Gln Lys Ala Ala Ala Gly Leu Met Ser Leu	
	450 455 460	
15	CTT CGT GAA ATG GGG AAA GGT TAT TTA GCT TTG TGT TCA TAC AAC TGC	1440
	Leu Arg Glu Met Gly Lys Gly Tyr Leu Ala Leu Cys Ser Tyr Asn Cys	
	465 470 475 480	
20	AAA GAA GCT ATA AAT ATT TTG AGC CAT CTA CCT TCT CAC CAC TAC AAT	1488
	Lys Glu Ala Ile Asn Ile Leu Ser His Leu Pro Ser His His Tyr Asn	
	485 490 495	
25	ACT GGT TGG GTA CTG TGC CAA ATT GGA AGG GCC TAT TTT GAA CTT TCA	1536
	Thr Gly Trp Val Leu Cys Gln Ile Gly Arg Ala Tyr Phe Glu Leu Ser	
	500 505 510	
30	GAG TAC ATG CAA GCT GAA AGA ATA TTC TCA GAG GTT AGA AGG ATT GAG	1584
	Glu Tyr Met Gln Ala Glu Arg Ile Phe Ser Glu Val Arg Arg Ile Glu	
	515 520 525	
35	AAT TAT AGA GTT GAA GGC ATG GAG ATC TAC TCT ACA ACA CTT TGG CAT	1632
	Asn Tyr Arg Val Glu Gly Met Glu Ile Tyr Ser Thr Thr Leu Trp His	
	530 535 540	
40	CTT CAA AAA GAT GTT GCT CTT TCA GTT CTG TCA AAA GAC TTA ACA GAC	1680
	Leu Gln Lys Asp Val Ala Leu Ser Val Leu Ser Lys Asp Leu Thr Asp	
	545 550 555 560	
45	ATG GAT AAA AAT TCG CCA GAG GCC TGG TGT GCT GCA GGG AAC TGT TTC	1728
	Met Asp Lys Asn Ser Pro Glu Ala Trp Cys Ala Ala Gly Asn Cys Phe	
	565 570 575	
50	AGT CTG CAA CGG GAA CAT GAT ATT GCA ATT AAA TTC TTC CAG AGA GCT	1776
	Ser Leu Gln Arg Glu His Asp Ile Ala Ile Lys Phe Phe Gln Arg Ala	
	580 585 590	
55	ATC CAA GTT GAT CCA AAT TAC GCT TAT GCC TAT ACT CTA TTA GGG CAT	1824
	Ile Gln Val Asp Pro Asn Tyr Ala Tyr Ala Tyr Thr Leu Leu Gly His	
	595 600 605	
60	GAG TTT GTC TTA ACT GAA GAA TTG GAC AAA GCA TTA GCT TGT TTT CGA	1872
	Glu Phe Val Leu Thr Glu Glu Leu Asp Lys Ala Leu Ala Cys Phe Arg	
	610 615 620	
65	AAT GCT ATC AGA GTC AAT CCT AGA CAT TAT AAT GCA TGG TAT GGT TTA	1920
	Asn Ala Ile Arg Val Asn Pro Arg His Tyr Asn Ala Trp Tyr Gly Leu	
	625 630 635 640	
	GGA ATG ATT TAT TAC AAG CAA GAA AAA TTC AGC CTT GCA GAA ATG CAT	1968

-46-

	Gly Met Ile Tyr Tyr Lys Gln Glu Lys Phe Ser Leu Ala Glu Met His	
	645 650 655	
5	TTC CAA AAA GCG CTT GAT ATC AAC CCT CAA AGT TCA GTT TTA CTT TGC Phe Gln Lys Ala Leu Asp Ile Asn Pro Gln Ser Ser Val Leu Leu Cys	2016
	660 665 670	
10	CAC ATT GGA GTA GTT CAA CAT GCA CTG AAA AAA TCA GAG AAG GCT TTG His Ile Gly Val Val Gln His Ala Leu Lys Lys Ser Glu Lys Ala Leu	2064
	675 680 685	
15	GAT ACC CTA AAC AAA GCC ATT GTC ATT GAT CCC AAG AAC CCT CTA TGC Asp Thr Leu Asn Lys Ala Ile Val Ile Asp Pro Lys Asn Pro Leu Cys	2112
	690 695 700	
20	AAA TTT CAC AGA GCC TCA GTT TTA TTT CGA AAT GAA AAA TAT AAG TCT Lys Phe His Arg Ala Ser Val Leu Phe Arg Asn Glu Lys Tyr Lys Ser	2160
	705 710 715 720	
25	GCT TTA CAA GAA CTT GAA GAA TTG AAA CAA ATT GTT CCC AAA GAA TCC Ala Leu Gln Glu Leu Glu Glu Leu Lys Gln Ile Val Pro Lys Glu Ser	2208
	725 730 735	
30	CTC GTT TAC TTC TTA ATA GGA AAG GTT TAC AAG AAG TTA GGT CAA ACG Leu Val Tyr Phe Leu Ile Gly Lys Val Tyr Lys Lys Leu Gly Gln Thr	2256
	740 745 750	
35	CAC CTC GCC CTG ATG AAT TTC TCT TGG GCT ATG GAT TTA GAT CCT AAA His Leu Ala Leu Met Asn Phe Ser Trp Ala Met Asp Leu Asp Pro Lys	2304
	755 760 765	
40	GGA GCC AAT AAC CAG ATT AAA GAG GCA ATT GAT AAG CGT TAT CTT CCA Gly Ala Asn Asn Gln Ile Lys Glu Ala Ile Asp Lys Arg Tyr Leu Pro	2352
	770 775 780	
45	GAT GAT GAG GAG CCA ATA ACC CAA GAA GAA CAG ATC ATG GGA ACA GAT Asp Asp Glu Glu Pro Ile Thr Gln Glu Glu Gln Ile Met Gly Thr Asp	2400
	785 790 795 800	
50	GAA TCC CAG GAG AGC AGC ATG ACA GAT GCG GAT GAC ACA CAA CTT CAT Glu Ser Gln Glu Ser Ser Met Thr Asp Ala Asp Asp Thr Gln Leu His	2448
	805 810 815	
55	GCA GCT GAA AGT GAT GAA TTT TAA Ala Ala Glu Ser Asp Glu Phe	2472
	820	

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3177 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

-47-

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..3177

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	ATG TCC AGC TCG CCG CTG TCC AAG AAA CGT CGC GTG TCC GGG CCT GAT	48
	Met Ser Ser Ser Pro Leu Ser Lys Lys Arg Arg Val Ser Gly Pro Asp	
	1 5 10 15	
10	CCA AAG CCG GGT TCT AAC TGC TCC CCT GCC CAG TCC GTG TTG TCC GAA	96
	Pro Lys Pro Gly Ser Asn Cys Ser Pro Ala Gln Ser Val Leu Ser Glu	
	20 25 30	
15	GTG CCC TCG GTG CCA ACC AAC GGA ATG GCC AAG AAC GGC AGT GAA GCA	144
	Val Pro Ser Val Pro Thr Asn Gly Met Ala Lys Asn Gly Ser Glu Ala	
	35 40 45	
20	GAC ATA GAC GAG GGC CTT TAC TCC CGG CAG CTG TAT GTG TTG GGC CAT	192
	Asp Ile Asp Glu Gly Leu Tyr Ser Arg Gln Leu Tyr Val Leu Gly His	
	50 55 60	
	GAG GCA ATG AAG CGG CTC CAG ACA TCC AGT GTC CTG GTA TCA GGC CTG	240
	Glu Ala Met Lys Arg Leu Gln Thr Ser Ser Val Leu Val Ser Gly Leu	
25	65 70 75 80	
	CGG GGC CTG GGC GTG GAG ATC GCT AAG AAC ATC ATC CTT GGT GGG GTC	288
	Arg Gly Leu Gly Val Glu Ile Ala Lys Asn Ile Ile Leu Gly Gly Val	
	85 90 95	
30	AAG GCT GTT ACC CTA CAT GAC CAG GGC ACT GCC CAG TGG GCT GAT CTT	336
	Lys Ala Val Thr Leu His Asp Gln Gly Thr Ala Gln Trp Ala Asp Leu	
	100 105 110	
35	TCC TCC CAG TTC TAC CTG CGG GAG GAG GAC ATC GGT AAA AAC CGG GCC	384
	Ser Ser Gln Phe Tyr Leu Arg Glu Glu Asp Ile Gly Lys Asn Arg Ala	
	115 120 125	
40	GAG GTA TCA CAG CCC CGC CTC GCT GAG CTC AAC AGC TAT GTG CCT GTC	432
	Glu Val Ser Gln Pro Arg Leu Ala Glu Leu Asn Ser Tyr Val Pro Val	
	130 135 140	
	ACT GCC TAC ACT GGA CCC CTC GTT GAG GAC TTC CTT AGT GGT TTC CAG	480
	Thr Ala Tyr Thr Gly Pro Leu Val Glu Asp Phe Leu Ser Gly Phe Gln	
45	145 150 155 160	
	GTG GTG GTG CTC ACC AAC ACC CCC CTG GAG GAC CAG CTG CGA GTG GGT	528
	Val Val Val Leu Thr Asn Thr Pro Leu Glu Asp Gln Leu Arg Val Gly	
	165 170 175	
50	GAG TTC TGT CAC AAC CGT GGC ATC AAG CTG GTG GTG GCA GAC ACG CGG	576
	Glu Phe Cys His Asn Arg Gly Ile Lys Leu Val Val Ala Asp Thr Arg	
	180 185 190	
55	GGC CTG TTT GGG CAG CTC TTC TGT GAC TTT GGA GAG GAA ATG ATC CTC	624
	Gly Leu Phe Gly Gln Leu Phe Cys Asp Phe Gly Glu Glu Met Ile Leu	
	195 200 205	

-48-

	ACA GAT TCC AAT GGG GAG CAG CCA CTC AGT GCT ATG GTT TCT ATG GTT Thr Asp Ser Asn Gly Glu Gln Pro Leu Ser Ala Met Val Ser Met Val 210 215 220	672
5	ACC AAG GAC AAC CCC GGT GTG GTT ACC TGC CTG GAT GAG GCC CGA CAC Thr Lys Asp Asn Pro Gly Val Val Thr Cys Leu Asp Glu Ala Arg His 225 230 235 240	720
10	GGG TTT GAG AGC GGG GAC TTT GTC TCC TTT TCA GAA GTA CAG GGC ATG Gly Phe Glu Ser Gly Asp Phe Val Ser Phe Ser Glu Val Gln Gly Met 245 250 255	768
15	GTT GAA CTC AAC GGA AAT CAG CCC ATG GAG ATC AAA GTC CTG GGT CCT Val Glu Leu Asn Gly Asn Gln Pro Met Glu Ile Lys Val Leu Gly Pro 260 265 270	816
20	TAT ACC TTT AGC ATC TGT GAC ACC TCC AAC TTC TCC GAC TAC ATC CGT Tyr Thr Phe Ser Ile Cys Asp Thr Ser Asn Phe Ser Asp Tyr Ile Arg 275 280 285	864
	GGA GGC ATC GTC AGT CAG GTC AAA GTA CCT AAG AAG ATT AGC TTT AAA Gly Gly Ile Val Ser Gln Val Lys Val Pro Lys Lys Ile Ser Phe Lys 290 295 300	912
25	TCC TTG GTG GCC TCA CTG GCA GAA CCT GAC TTT GTG GTG ACG GAC TTC Ser Leu Val Ala Ser Leu Ala Glu Pro Asp Phe Val Val Thr Asp Phe 305 310 315 320	960
30	GCC AAG TTT TCT CGC CCT GCC CAG CTG CAC ATT GGC TTC CAG GCC CTG Ala Lys Phe Ser Arg Pro Ala Gln Leu His Ile Gly Phe Gln Ala Leu 325 330 335	1008
35	CAC CAG TTC TGT GCT CAG CAT GGC CGG CCA CCT CGG CCC CGC AAT GAG His Gln Phe Cys Ala Gln His Gly Arg Pro Pro Arg Pro Arg Asn Glu 340 345 350	1056
40	GAG GAT GCA GCA GAA CTG GTA GCC TTA GCA CAG GCT GTG AAT GCT CGA Glu Asp Ala Ala Glu Leu Val Ala Leu Ala Gln Ala Val Asn Ala Arg 355 360 365	1104
	GCC CTG CCA GCA GTG CAG CAA AAT AAC CTG GAC GAG GAC CTC ATC CGG Ala Leu Pro Ala Val Gln Gln Asn Asn Leu Asp Glu Asp Leu Ile Arg 370 375 380	1152
45	AAG CTG GCA TAT GTG GCT GCT GGG GAT CTG GCA CCC ATA AAC GCC TTC Lys Leu Ala Tyr Val Ala Ala Gly Asp Leu Ala Pro Ile Asn Ala Phe 385 390 395 400	1200
50	ATT GGG GGC CTG GCT GCC CAG GAA GTC ATG AAG GCC TGC TCC GGG AAG Ile Gly Gly Leu Ala Ala Gln Glu Val Met Lys Ala Cys Ser Gly Lys 405 410 415	1248
55	TTC ATG CCC ATC ATG CAG TGG CTA TAC TTT GAT GCC CTT GAG TGT CTC Phe Met Pro Ile Met Gln Trp Leu Tyr Phe Asp Ala Leu Glu Cys Leu 420 425 430	1296
	CCT GAG GAC AAA GAG GTC CTC ACA GAG GAC AAG TGC CTC CAG CGC CAG Pro Glu Asp Lys Glu Val Leu Thr Glu Asp Lys Cys Leu Gln Arg Gln 1344	

	435	440	445	
5	AAC CGT TAT GAC GGG CAA GTG GCT GTG TTT GGC TCA GAC CTG CAA GAG Asn Arg Tyr Asp Gly Gln Val Ala Val Phe Gly Ser Asp Leu Gln Glu 450 455 460	1392		
10	AAG CTG GGC AAG CAG AAG TAT TTC CTG GTG GGT GCG GGG GCC ATT GGC Lys Leu Gly Lys Gln Lys Tyr Phe Leu Val Gly Ala Gly Ala Ile Gly 465 470 475 480	1440		
15	TGT GAG CTG CTC AAG AAC TTT GCC ATG ATT GGG CTG GGC TGC GGG GAG Cys Glu Leu Leu Lys Asn Phe Ala Met Ile Gly Leu Gly Cys Gly Glu 485 490 495	1488		
20	GGT GGA GAA ATC ATC GTT ACA GAC ATG GAC ACC ATT GAG AAG TCA AAT Gly Gly Glu Ile Ile Val Thr Asp Met Asp Thr Ile Glu Lys Ser Asn 500 505 510	1536		
25	CTG AAT CGA CAG TTT CTT TTC CGG CCC TGG GAT GTC ACG AAG TTA AAG Leu Asn Arg Gln Phe Leu Phe Arg Pro Trp Asp Val Thr Lys Leu Lys 515 520 525	1584		
30	TCT GAC ACG GCT GCT GCA GCT GTG CGC CAA ATG AAT CCA CAT ATC CGG Ser Asp Thr Ala Ala Ala Ala Val Arg Gln Met Asn Pro His Ile Arg 530 535 540	1632		
35	GTG ACA AGC CAC CAG AAC CGT GTG GGT CCT GAC ACG GAG CGC ATC TAT Val Thr Ser His Gln Asn Arg Val Gly Pro Asp Thr Glu Arg Ile Tyr 545 550 555 560	1680		
40	GAT GAC GAT TTT TTC CAA AAC CTA GAT GGC GTG GCC AAT GCC CTG GAC Asp Asp Asp Phe Phe Gln Asn Leu Asp Gly Val Ala Asn Ala Leu Asp 565 570 575	1728		
45	AAC GTG GAT GCC CGC ATG TAC ATG GAC CGC CGC TGT GTC TAC TAC CGG Asn Val Asp Ala Arg Met Tyr Met Asp Arg Arg Cys Val Tyr Tyr Arg 580 585 590	1776		
50	AAG CCA CTG CTG GAG TCA GGC ACA CTG GGC ACC AAA GGC AAT GTG CAG Lys Pro Leu Leu Glu Ser Gly Thr Leu Gly Thr Lys Gly Asn Val Gln 595 600 605	1824		
55	GTG GTG ATC CCC TTC CTG ACA GAG TCG TAC AGT TCC AGC CAG GAC CCA Val Val Ile Pro Phe Leu Thr Glu Ser Tyr Ser Ser Ser Gln Asp Pro 610 615 620	1872		
60	CCT GAG AAG TCC ATC CCC ATC TGT ACC CTG AAG AAC TTC CCT AAT GCC Pro Glu Lys Ser Ile Pro Ile Cys Thr Leu Lys Asn Phe Pro Asn Ala 625 630 635 640	1920		
65	ATC GAG CAC ACC CTG CAG TGG GCT CGG GAT GAG TTT GAA GGC CTC TTC Ile Glu His Thr Leu Gln Trp Ala Arg Asp Glu Phe Glu Gly Leu Phe 645 650 655	1968		
70	AAG CAG CCA GCA GAA AAT GTC AAC CAG TAC CTC ACA GAC CCC AAG TTT Lys Gln Pro Ala Glu Asn Val Asn Gln Tyr Leu Thr Asp Pro Lys Phe 660 665 670	2016		

-50-

	GTG GAG CGA ACA CTG CGG CTG GCA GGC ACT CAG CCC TTG GAG GTG CTG	2064
	Val Glu Arg Thr Leu Arg Leu Ala Gly Thr Gln Pro Leu Glu Val Leu	
	675 680 685	
5	GAG GCT GTG CAG CGC AGC CTG GTG CTG CAG CGA CCA CAG ACC TGG GCT	2112
	Glu Ala Val Gln Arg Ser Leu Val Leu Gln Arg Pro Gln Thr Trp Ala	
	690 695 700	
10	GAC TGC GTG ACC TGG GCC TGC CAC CAC TGG CAC ACC CAG TAC TCG AAC	2160
	Asp Cys Val Thr Trp Ala Cys His His Trp His Thr Gln Tyr Ser Asn	
	705 710 715 720	
15	AAC ATC CGG CAG CTG CTG CAC AAC TTC CCT CCT GAC CAG CTC ACA AGC	2208
	Asn Ile Arg Gln Leu Leu His Asn Phe Pro Pro Asp Gln Leu Thr Ser	
	725 730 735	
20	TCA GGA GCG CCG TTC TGG TCT GGG CCC AAA CGC TGT CCA CAC CCG CTC	2256
	Ser Gly Ala Pro Phe Trp Ser Gly Pro Lys Arg Cys Pro His Pro Leu	
	740 745 750	
	ACC TTT GAT GTC AAC AAT CCC CTG CAT CTG GAC TAT GTG ATG GCT GCT	2304
	Thr Phe Asp Val Asn Asn Pro Leu His Leu Asp Tyr Val Met Ala Ala	
	755 760 765	
25	GCC AAC CTG TTT GCC CAG ACC TAC GGG CTG ACA GGC TCT CAG GAC CGA	2352
	Ala Asn Leu Phe Ala Gln Thr Tyr Gly Leu Thr Gly Ser Gln Asp Arg	
	770 775 780	
30	GCT GCT GTG GCC ACA TTC CTG CAG TCT GTG CAG GTC CCC GAA TTC ACC	2400
	Ala Ala Val Ala Thr Phe Leu Gln Ser Val Gln Val Pro Glu Phe Thr	
	785 790 795 800	
35	CCC AAG TCT GGC GTC AAG ATC CAT GTT TCT GAC CAG GAG CTG CAG AGC	2448
	Pro Lys Ser Gly Val Lys Ile His Val Ser Asp Gln Glu Leu Gln Ser	
	805 810 815	
40	GCC AAT GCC TCT GTT GAT GAC AGT CGT CTA GAG GAG CTC AAA GCC ACT	2496
	Ala Asn Ala Ser Val Asp Asp Ser Arg Leu Glu Glu Leu Lys Ala Thr	
	820 825 830	
	CTG CCC AGC CCA GAC AAG CTC CCT GGA TTC AAG ATG TAC CCC ATT GAC	2544
	Leu Pro Ser Pro Asp Lys Leu Pro Gly Phe Lys Met Tyr Pro Ile Asp	
	835 840 845	
45	TTT GAG AAG GAT GAT GAC AGC AAC TTT CAT ATG GAT TTC ATC GTG GCT	2592
	Phe Glu Lys Asp Asp Asp Ser Asn Phe His Met Asp Phe Ile Val Ala	
	850 855 860	
50	GCA TCC AAC CTC CGG GCA GAA AAC TAT GAC ATT CCT TCT GCA GAC CGG	2640
	Ala Ser Asn Leu Arg Ala Glu Asn Tyr Asp Ile Pro Ser Ala Asp Arg	
	865 870 875 880	
55	CAC AAG AGC AAG CTG ATT GCA GGG AAG ATC ATC CCA GCC ATT GCC ACG	2688
	His Lys Ser Lys Leu Ile Ala Gly Lys Ile Ile Pro Ala Ile Ala Thr	
	885 890 895	
	ACC ACA GCA GCC GTG GTT GGC CTT GTG TGT CTG GAA CTG TAC AAG GTT	2736
	Thr Thr Ala Ala Val Val Gly Leu Val Cys Leu Glu Leu Tyr Lys Val	

-51-

	900	905	910	
5	GTG CAG GGG CAC CGA CAG CTT GAC TCC TAC AAG AAT GGT TTC CTC AAC Val Gln Gly His Arg Gln Leu Asp Ser Tyr Lys Asn Gly Phe Leu Asn 915 920 925	2784		
10	TTG GCC CTG CCT TTC TTT GGT TTC TCT GAA CCC CTT GCC GCA CCA CGT Leu Ala Leu Pro Phe Phe Gly Phe Ser Glu Pro Leu Ala Ala Pro Arg 930 935 940	2832		
15	CAC CAG TAC TAT AAC CAA GAG TGG ACA TTG TGG GAT CGC TTT GAG GTA His Gln Tyr Tyr Asn Gln Glu Trp Thr Leu Trp Asp Arg Phe Glu Val 945 950 955 960	2880		
20	CAA GGG CTG CAG CCT AAT GGT GAG GAG ATG ACC CTC AAA CAG TTC CTC Gln Gly Leu Gln Pro Asn Gly Glu Glu Met Thr Leu Lys Gln Phe Leu 965 970 975	2928		
25	GAC TAT TTT AAG ACA GAG CAC AAA TTA GAG ATC ACC ATG CTG TCC CAG Asp Tyr Phe Lys Thr Glu His Lys Leu Glu Ile Thr Met Leu Ser Gln 980 985 990	2976		
30	GGC GTG TCC ATG CTC TAT TCC TTC TTC ATG CCA GCT GCC AAG CTC AAG Gly Val Ser Met Leu Tyr Ser Phe Phe Met Pro Ala Ala Lys Leu Lys 995 1000 1005	3024		
35	GAA CGG TTG GAT CAG CCG ATG ACA GAG ATT GTG AGC CGT GTG TCG AAG Glu Arg Leu Asp Gln Pro Met Thr Glu Ile Val Ser Arg Val Ser Lys 1010 1015 1020	3072		
40	CGA AAG CTG GGC CGC CAC GTG CGG GCG CTG GTG CTT GAG CTG TGC TGT Arg Lys Leu Gly Arg His Val Arg Ala Leu Val Leu Glu Leu Cys Cys 1025 1030 1035 1040	3120		
45	AAC GAC GAG AGC GGC GAG GAT GTC GAG GTT CCC TAT GTC CGA TAC ACC Asn Asp Glu Ser Gly Glu Asp Val Glu Val Pro Tyr Val Arg Tyr Thr 1045 1050 1055	3168		
50	ATC CGC TG Ile Arg	3177		

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 453 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..453

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

SUBSTITUTE SHEET (RULE 26)

-52-

	CGG CAC GAG AGA ATC CAC AAG GAA TTG AAT GAT CTG GCA CGG GAC CCT	48
	Arg His Glu Arg Ile His Lys Glu Leu Asn Asp Leu Ala Arg Asp Pro	
5	1 5 10 15	
	CCA GCA CAG TGT TCA GCA GGT CCT GTT GGA GAT GAT ATG TTC CAT TGG	96
	Pro Ala Gln Cys Ser Ala Gly Pro Val Gly Asp Asp Met Phe His Trp	
	20 25 30	
10	CAA GCT ACA ATA ATG GGG CCA AAT GAC AGT CCC TAT CAG GGT GGA GTA	144
	Gln Ala Thr Ile Met Gly Pro Asn Asp Ser Pro Tyr Gln Gly Gly Val	
	35 40 45	
	TTT TTC TTG ACA ATT CAT TTC CCA ACA GAT TAC CCC TTC AAA CCA CCT	192
15	Phe Phe Leu Thr Ile His Phe Pro Thr Asp Tyr Pro Phe Lys Pro Pro	
	50 55 60	
	AAG GTT GCA TTT ACA GTT GCA TTT ACC ACA AGA ATT TAT CAT CCA AAT	240
20	Lys Val Ala Phe Thr Val Ala Phe Thr Thr Arg Ile Tyr His Pro Asn	
	65 70 75 80	
	ATT AAC AGT AAT GGC AGC ATT TGT CTT GAT ATT CTA CGA TCA CAG TGG	288
	Ile Asn Ser Asn Gly Ser Ile Cys Leu Asp Ile Leu Arg Ser Gln Trp	
25	85 90 95	
	TCT CCA GCA CTA ACT ATT TCA AAA GTA CTC TTG TCC ATC TGT TCT CTG	336
	Ser Pro Ala Leu Thr Ile Ser Lys Val Leu Leu Ser Ile Cys Ser Leu	
	100 105 110	
30	TTG TGT GAT CCC AAT CCA GAT GAT CCT TTA GTG CCT GAG ATT GCT CGG	384
	Leu Cys Asp Pro Asn Pro Asp Asp Pro Leu Val Pro Glu Ile Ala Arg	
	115 120 125	
	ATC TAC CAA ACA GAT AGA GAA AAG TAC AAC AGA ATA GCT CGG GAA TGG	432
35	Ile Tyr Gln Thr Asp Arg Glu Lys Tyr Asn Arg Ile Ala Arg Glu Trp	
	130 135 140	
	ACT CAG AAG TAT GCG ATG TA	453
	Thr Gln Lys Tyr Ala Met	
40	145 150	

1. An assay for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein, comprising:

- 5 (i) providing a cell-free ubiquitin-conjugating system, other than a whole lysate, which system comprises a cell-cycle regulatory protein, an E2 enzyme, a mitotic destruction complex (MDC), and ubiquitin, under conditions which promote MDC-dependent ubiquitination of the regulatory protein;
- (ii) contacting the ubiquitin-conjugating system with a candidate agent;
- (iii) measuring a level of ubiquitination of the regulatory protein in the presence of the candidate agent; and
- 10 (iv) comparing the measured level of ubiquitination in the presence of the candidate agent with a level of ubiquitination of the regulatory protein in the absence of the candidate agent,

wherein a statistically significant decrease in ubiquitination of the regulatory protein in the presence of the candidate agent is indicative of an inhibitor of ubiquitination of the regulatory protein.

15

2. An assay for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein, comprising:

- 20 (i) providing a ubiquitin-conjugating system, which system comprises a reconstituted protein mixture including a cell-cycle regulatory protein, an E2 enzyme, a mitotic destruction complex (MDC), and ubiquitin, under conditions which promote MDC-dependent ubiquitination of the regulatory protein;
- (ii) contacting the ubiquitin-conjugating system with a candidate agent;
- (iii) measuring a level of ubiquitination of the regulatory protein in the presence of the candidate agent; and
- 25 (iv) comparing the measured level of ubiquitination in the presence of the candidate agent with a level of ubiquitination of the regulatory protein in the absence of the candidate agent,

wherein a decrease in ubiquitination of the regulatory protein in the presence of the candidate agent is indicative of an inhibitor of ubiquitination of the regulatory protein.

30

3. The assay of claim 2, wherein the MDC comprises CDC27 and CDC16.
4. The assay of claim 2, wherein the MDC comprises a 20S complex isolated from a mitotically-regulated cell lysate fraction.
- 35
5. The assay of claim 2, wherein the ubiquitin is provided in a form selected from a group consisting of:

- (i) an unconjugated ubiquitin, in which case the ubiquitin-conjugating system further comprises an E1 ubiquitin-activating enzyme (E1), an E2 ubiquitin-conjugating enzyme (E2), and adenosine triphosphate;
- (ii) an activated E1:ubiquitin complex, in which case the ubiquitin-conjugating system further comprises an E2; and
- (iii) an activated E2:ubiquitin complex.
6. The assay of claim 2, wherein the E2 enzyme is selected from the group consisting of UBC4 and UBC5.
7. The assay of claim 2, wherein at least one of the ubiquitin and the regulatory protein comprises a detectable label, and the level of ubiquitin-conjugated regulatory protein is quantified by detecting the label in at least one of the regulatory protein, the ubiquitin, and the ubiquitin-conjugated regulatory protein.
8. The method of claim 7, wherein the label is selected from a group consisting of radioisotopes, fluorescent compounds, enzymes, and enzyme co-factors.
9. The assay of claim 7, wherein the detectable label is a protein having a measurable activity, and the regulatory protein is fusion protein including the detectable label.
10. The assay of claim 2, wherein the amount of ubiquitin-conjugated regulatory protein is quantified by an immunoassay.
11. An assay for identifying an inhibitor of ubiquitin-mediated proteolysis of a cyclin, comprising:
- (i) providing a ubiquitin-conjugating system, comprising a reconstituted protein mixture including
- a cyclin,
- an E2 enzyme,
- a mitotic destruction complex including a CDC27 protein and a CDC16 protein, and
- ubiquitin,
- under conditions which promote ubiquitination of the cyclin;
- (ii) contacting the ubiquitin-conjugating system with a candidate agent;
- (iii) measuring a level of ubiquitination of the regulatory protein in the presence of the candidate agent; and

- (iv) comparing the measured level of ubiquitination of the cyclin in the presence of the candidate agent with a level of ubiquitination of the cyclin in the absence of the candidate agent,

wherein a decrease in ubiquitination of the cyclin in the presence of the candidate agent is indicative of an inhibitor of ubiquitination of the cyclin.

12. The assay of claim 11, wherein the ubiquitin is provided in a form selected from a group consisting of:

- (i) an unconjugated ubiquitin, in which case the ubiquitin-conjugating system further comprises an E1 ubiquitin-activating enzyme (E1), an E2 ubiquitin-conjugating enzyme (E2), and adenosine triphosphate;
- (ii) an activated E1:ubiquitin complex, in which case the ubiquitin-conjugating system further comprises an E2; and
- (iii) an activated E2:ubiquitin complex.

13. The assay of claim 11, wherein the complex which includes a CDC27 and a CDC16 is a 20S complex isolated from a mitotically-regulated cell lysate fraction.

14. The assay of claim 11, wherein the E2 enzyme is selected from the group consisting of UBC4 and UBC5.

15. The assay of claim 11, wherein the cyclin is cyclin B.

16. The assay of claim 11, wherein at least one of the ubiquitin and the regulatory protein comprises a detectable label, and the level of ubiquitin-conjugated regulatory protein is quantified by detecting the label in at least one of the regulatory protein, the ubiquitin, and the ubiquitin-conjugated regulatory protein.

17. An assay for identifying an inhibitor of ubiquitin-mediated proteolysis of a cyclin protein, comprising:

- (i) providing a ubiquitin-conjugating system, which system comprises a cyclin protein, a mitotic destruction complex including a CDC27 and a CDC16, an E2 enzyme selected from the group consisting of UBC4 and UBC5, and ubiquitin, under conditions which promote ubiquitination of the regulatory protein, wherein at least one of the CDC27, CDC16 or E2 enzyme is provided to the system as a purified, semi-purified or recombinant preparation;
- (ii) contacting the ubiquitin-conjugating system with a candidate agent;
- (iii) measuring a level of ubiquitination of the cyclin protein in the presence of the candidate agent; and

- (iv) comparing the measured level of ubiquitination in the presence of the candidate agent with a level of ubiquitination of the cyclin protein in the absence of the candidate agent,

wherein a decrease in ubiquitination of the cyclin protein in the presence of the candidate agent is indicative of an inhibitor of ubiquitination of the cyclin protein.

18. The assay of claim 17, wherein the cyclin protein is a cyclin including a destruction box.

19. The assay of claim 17, wherein the cyclin protein is a B-type cyclin.

20. The assay of claim 17, wherein the ubiquitin is provided in a form selected from a group consisting of:

- (i) an unconjugated ubiquitin, in which case the ubiquitin-conjugating system further comprises an E1 ubiquitin-activating enzyme (E1), an E2 ubiquitin-conjugating enzyme (E2), and adenosine triphosphate;
- (ii) an activated E1:ubiquitin complex, in which case the ubiquitin-conjugating system further comprises an E2; and
- (iii) an activated E2:ubiquitin complex.

21. The assay of claim 17, wherein mitotic destruction complex is a 20S complex isolated from a mitotically-regulated cell lysate fraction.

22. The assay of claim 17, wherein at least one of the ubiquitin and the cyclin protein comprises a detectable label, and the level of ubiquitin-conjugated cyclin protein is quantified by detecting the label in at least one of the cyclin protein, the ubiquitin, and the ubiquitin-conjugated cyclin protein.

23. The assay of claim 17, wherein the amount of ubiquitin-conjugated cyclin protein is quantified by an immunoassay.

24. An assay for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein, comprising:

- (i) providing a ubiquitin-conjugating system, comprising cell extract including a cell-cycle regulatory protein, a complex including a CDC27 and a CDC16, an E2 enzyme, and ubiquitin, under conditions which promote ubiquitination of the regulatory protein, and wherein the semi-purified cell extract is charged with at least one component of a ubiquitin-conjugation pathway;
- (ii) contacting the ubiquitin-conjugating system with a candidate agent;

(iii) measuring a level of ubiquitination of the regulatory protein in the presence of the candidate agent; and

(iv) comparing the measured level of ubiquitination in the presence of the candidate agent with a level of ubiquitination of the regulatory protein in the absence of the candidate agent,

wherein a decrease in ubiquitination of the regulatory protein in the presence of the candidate agent is indicative of an inhibitor of ubiquitination of the regulatory protein.

25. The assay of claim 24, wherein the regulatory protein is selected from a group consisting of a cyclin, p53, myc, and fos.

26. The assay of claim 24, wherein the complex which includes a CDC27 and a CDC16 is a 20S complex.

27. The assay of claim 24, wherein the E2 enzyme is selected from the group consisting of UBC4 and UBC5.

28. The assay of claim 24, wherein at least one of the ubiquitin and the regulatory protein comprises a detectable label, and the level of ubiquitin-conjugated regulatory protein is quantified by detecting the label in at least one of the regulatory protein, the ubiquitin, and the ubiquitin-conjugated regulatory protein.

29. An assay for identifying an agent which competitively inhibits binding of a mitotic destruction complex with a cell-cycle regulatory protein, comprising:

(i) forming a mixture comprising: at least one protein component of a mitotic destruction complex (MDC), a cell-cycle regulatory protein which binds to said MDC, and a candidate agent;

(ii) measuring a level of binding between the regulatory protein and the MDC in the presence of the candidate agent; and



(iv) comparing the measured level of binding in the presence of the candidate agent with a level of binding of the regulatory protein to the MDC in the absence of the candidate agent,

wherein a statistically significant decrease in binding of the regulatory protein to the MDC in the presence of the candidate agent is indicative of an agent which competitively inhibits binding of a mitotic destruction complex with a cell-cycle regulatory protein.

30. An assay for identifying an agent which competitively inhibits binding of a mitotic destruction complex with a ubiquitin conjugating enzyme, comprising:

- (i) forming a mixture comprising: at least one protein component of a mitotic destruction complex (MDC), an E2 enzyme which binds to said MDC, and a candidate agent;
- (ii) measuring a level of binding between the E2 enzyme and the MDC in the presence of the candidate agent; and
- (iv) comparing the measured level of binding in the presence of the candidate agent with a level of binding of the E2 enzyme to the MDC in the absence of the candidate agent,

wherein a statistically significant decrease in binding of the E2 enzyme to the MDC in the presence of the candidate agent is indicative of an agent which competitively inhibits binding of a mitotic destruction complex with an E2 enzyme.

**FIG. 1****FIG. 2**

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/05643

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12Q1/25 G01N33/68 G01N33/58		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,95 18974 (MITOTIX, INC.) 13 July 1995 see claims 1-21	1-30
A	--- WO,A,92 20804 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 26 November 1992 see the whole document -----	1-30
<div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Further documents are listed in the continuation of box C. </div> <div> <input checked="" type="checkbox"/> Patent family members are listed in annex. </div> </div>		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">10 September 1996</div>		Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">03. 10. 96</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016		Authorized officer <div style="text-align: center; font-size: 1.2em;">Griffith, G</div>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/05643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9518974	13-07-95	AU-A- 1866995	01-08-95
		AU-A- 2763095	21-12-95
		WO-A- 9533052	07-12-95

WO-A-9220804	26-11-92	US-A- 5340736	23-08-94
		AU-B- 666854	29-02-96
		AU-A- 2027592	30-12-92
		CA-A- 2102195	14-11-92
		EP-A- 0591316	13-04-94
		HU-A- 66512	28-11-94
		JP-T- 6507786	08-09-94
